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ABSTRACT 
Clays have been used for centuries as ‘ancient medicine’ for their therapeutic 
benefits. One particular clay, calcium montmorillonite, has historically been used as an 
anti-caking agent in animal feeds, but has also demonstrated the ability to bind toxins 
and alleviate infectious diarrhea.  The full breadth of therapeutic applications and 
molecular mechanisms of montmorillonite is still unknown.  Therefore, the purpose of 
this research was to explore novel therapeutic applications for NovaSil (NS), a calcium 
montmorillonite clay to reduce the risk of aflatoxicosis in farm-raised fish and alleviate 
gastrointestinal inflammation and dysbiosis in a mouse model of Crohn’s disease (CD).  
Aflatoxin B1 (AFB1) is a fungal mycotoxin that commonly contaminates corn 
and peanut crops. It is produced by the fungi Aspergillus flavus and A. parasiticus during 
times of drought or due to improper post-harvest storage. Aflatoxin B1 is known to cause 
hepatocellular carcinoma, immunosuppression and growth stunting in several species.  
Recently, incorporation of plant-based alternatives into feed for farm-raised fish has 
become a trend, thereby increasing the risk for mycotoxin contamination. Inexpensive 
strategies to reduce AFB1 exposure are needed. Calcium montmorillonite clay, which is 
both inexpensive and abundant, has a dioctahedral structure that is known to sequester 
AFB1 in its negatively-charged interlayer, thereby reducing systemic bioavailability. 
There is also some evidence to suggest that calcium montmorillonite clays may possess 
gastrointestinal anti-inflammatory properties.  
NovaSil was used as a strategy to reduce the effects of AFB1 in Nile tilapia 
(Oreochromis niloticus) and red drum (Scieanops ocellatus). Juvenile tilapia and red 
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drum were dosed with AFB1 and NS over the course of 10 and 7 weeks, respectively.  
Additionally, proinflammatory cytokine-clay binding was characterized using isothermal 
analysis, X-ray diffraction (XRD) and transmission electron microscopy (TEM). 
Furthermore, a TNBS (2,4,6-Trinitrobenzenesulfonic acid)-colitis gastrointestinal mouse 
model was employed to study the anti-inflammatory properties of NS and its ability to 
protect the gut microbiome.  
Results suggest that NS can prevent aflatoxicosis in red drum at a 2% inclusion 
level over the course of 7 weeks. NovaSil also prevented some toxicity in Nile tilapia; 
however, these results were not significant.  In vitro results also indicate that NS sorbs 
proinflammatory cytokines such as TNFα and IL-1β in its interlayers. Additionally, NS 
was found to reduce serum pro-inflammatory cytokine levels in TNBS-induced mice and 
reduce gut dysbiosis. These results could positively impact both human and animal 
populations with AFB1 exposure and/or chronic gastrointestinal inflammation.   
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1. INTRODUCTION 
1.1 Aflatoxin 
1.1.1 Origins of aflatoxin contamination  
Aflatoxins are toxic fungal metabolites produced by the fungi Aspergillus flavus 
and A. parasiticus.  These fungi typically grow in tropical and subtropical climates on 
multiple agricultural products  [1]. While some agricultural commodities are 
contaminated in the field, the majority of crops are contaminated during the post-harvest 
storage  [2]. Aflatoxins can frequently contaminate feedstuffs such as peanuts, corn, 
soybean, maize, rice, dried fish and fishmeals.  These feed components are used for both 
commercial animal feeds and also for human consumption. Aflatoxin B1 (AFB1), one of 
the aflatoxin metabolites, is a complete carcinogen causing initiation and promotion  [3, 
4]. Often, AFB1 occurs in feed concurrently with other mycotoxins such as fumonisin B1 
(FB1), ochratoxin (OTA), and zearalenone (ZEA)  [5, 6].   
A. Flavus is the most abundant soil-borne mold and can be found in various 
environments. This fungus is saprophytic, a term used to describe its ability to grow on 
wood and organic matter and can thrive in temperatures ranging from 12 to 48ᵒC. A. 
Flavus is exceedingly heat tolerant, which contributes to its resilience on agricultural 
commodities in both humans and animals. A. flavus has the ability to infect maize, 
cotton, peanuts and tree nuts. A. flavus can also attack monocot and dicot seeds above 
and below the surface. In corn, it typically causes “ear rot” especially when plants are 
stressed at high ambient temperatures. Natural sources of stress such as insects, hail and 
disease can predispose plants to AFB1 contamination  [7].   
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The fungal cell wall of A. flavus is the key characteristic that influences the 
pathogenicity and the fungal hyphae is responsible for penetrating the host’s cell wall. 
Aflatoxin contamination is not evenly distributed throughout crops and “hot spots” are a 
notable issue, especially in maize. While A. flavus is typically responsible for producing 
AFB1, A. parasiticus is also responsible for producing aflatoxins such as AFG1, AFG2 
and AFM1.  
While temperature is the most influential factor in pre-harvest aflatoxin 
contamination, moisture is a secondary influential impetus. Water stress occurring from 
40 to 75 days before harvest causes aflatoxin contamination in mature kernels. Drought 
for 20 days with normal soil temperatures (28-30.5°C) resulted in A. flavus 
contamination in 19.5% of peanut crops, and 75% of damaged peanuts with up to 784 
ppb AFB1 contamination [8]. While aflatoxin is a world-wide issue, extensive economic 
losses have occurred in the United States during times of drought in both peanut and 
corn crops as well as livestock  [9, 10]. 
1.1.2 Aflatoxin metabolites  
Aflatoxins and their metabolites vary considerably in prevalence and toxicity. 
Aflatoxin B1 is one of the most toxic congeners because of its carcinogenic, 
immunosuppressive and growth stunting capabilities. Aflatoxin B1, B2, G1 and G2 
commonly contaminate grains and agricultural crops. Aflatoxin M1 and M2 are prevalent 
in milk and dairy products.  Action limits for AFB1 in dairy feed and AFM1 in milk and 
dairy products are country specific, however, in the United States, the limit for  dairy 
feed is 20 ppb aflatoxin B1 and 0.5 ppb aflatoxin M1 in milk When animal feed or milk is 
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above these levels, it is  rejected for animal and human consumption , which results in 
nearly a billion USD loss per year  [7].  
1.1.3 Aflatoxin B1 metabolism  
Aflatoxin B1 is metabolized in three different stages: bioactivation, conjugation 
and deconjugation. In the bioactivation phase, AFB1 becomes hydroxylated forming 
AFM1, aflatoxicol, and the AFB1 8,9 epoxide. Other metabolites, such as AFQ1 and 
AFB2, are produced from the reaction but are not as toxic as the other metabolites. 
Because the 8, 9 epoxide is very unstable, often it will bind to DNA and other 
nucleophilic compounds (Fig. 1). This causes the formation of multiple DNA adducts 
including AFB1-N7-guanine, -pyrimidyl, and -diol adducts  [11]. Carbon 8 on AFB1 
reacts with the N7 position of guanine to form the 8,9-dihydro-8-(N7-guanyl)-9-hydroxy-
AFB1 adduct. Multiple CYP450 isoenzymes are responsible for AFB1 epoxidation, such 
as CYP2C11. CYP1A2 is also capable of catalyzing the oxidation of AFB1 to AFM1 in 
the rat liver  [12].  Mammalian cytochromes and piscine cytochromes differ in 
nomenclature according to the Cytochrome P450 Nomenclature Committee. Some of the 
Phase I metabolizing enzymes that are responsible for AFB1 biotransformation in fish 
include CYPLMC1- CYPLMC5  [13].  
There are five known cytochromes that are responsible for transforming AFB1 
into the epoxidated form in humans. These include CYPs1A2, 2A6, 2B7, 3A3, and 3A4, 
with 1A2 and 3A4 enzymes which cause the majority of epoxidation. Inhibition of liver 
microsomes with CYP450 inhibitors such as furafylline and troleandomycin have shown 
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to be very effective in inhibiting CYP1A2 and CYP3A4, respectively, thereby 
preventing formation of the AFB1 epoxide  [14]. 
 Following bioactivation (phase I metabolism), conjugation (phase II 
metabolism) is facilitated via glutathione-S transferase (GST), β-glucoronidase and/or 
sulfate transferase enzymes to produce products such as AFB1-glutathione, the major 
metabolite, and other lesser metabolites including AFB1-glucoronide and AFB1-sulfate. 
The amount of GST activity in rodents is inversely related to species susceptibility to 
AFB1-induced hepatocarcinogenesis.  
Intestinal bacteria are also responsible for deconjugation and can recirculate 
AFB1 metabolites which ultimately reach the liver  [15]. Aflatoxin B1, a direct mutagen, 
forms an epoxide through cytochrome P450-mediated oxidation   [16] (Fig. 1). In 
addition, proto-oncogenes of the ras family are activated with the formation of the AFB1 
adduct and can cause a direct transversion of guanine to thiamine in p53 tumor 
suppressor genes in the liver  [17]. RNA damage and interaction with intercellular 
proteins are also consequences of AFB1 exposure. Proteins can bind to the epoxide in the 
same way that the epoxide binds to DNA, and albumin is the most common protein that 
is known to bind to AFB1, creating the AFB1-albumin adduct that can be detected in 
serum  [18]. In addition to CYP-450 mediated oxidation as the dominant pathway in 
AFB1 epoxidation, other pathways have also been identified that contribute to AFB1 
activation. Prostaglandin H synthase (PHS) can also cause epoxidation; however, levels 
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Figure 1. Aflatoxin metabolism. Aflatoxin metabolism results in urinary excretion of metabolites. (adapted from  [16].)
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are largely tissue-dependent [19]. Lipooxygenases in the liver and kidney of mammals 
can also activate AFB1-DNA binding. 
Further oxidation of AFB1 at the 8,9 carbon may also form aflatoxin B2α. This 
particular metabolite can contribute to the formation of Schiff bases with amines, but is 
still less toxic than AFB1. Epoxide hydrolase can convert the AFB1 epoxide to the AFB1-
dihydrodiol. Therefore, AFB1-DNA binding can be reduced with the presence of epoxide 
hydrolase, even in the absence of GST  [20].     
1.1.4 Aflatoxin toxicity in multiple species 
One of the first recorded instances of AFB1 carcinogenicity was demonstrated in 
farm-raised rainbow trout. In the 1960s, a trout farm had a series of aflatoxin outbreaks 
and ultimately, the source was traced back to a batch of heavily contaminated cottonseed 
meal. To this day, trout are used as a model for hepatocellular carcinoma (HCC), due to 
their relatively high level of phase I metabolizing enzymes and relatively low level of 
phase II metabolizing enzymes  [21]. Aflatoxin-induced hepatocellular carcinoma is 
often dictated by the proportion of phase I and phase II metabolizing enzymes in the 
liver. Within a few years after the trout aflatoxicosis outbreak, “Turkey X” Disease was 
discovered and was ultimately attributed to AFB1  [22]. The disease was characterized by 
odd behavior followed by coma and death. Upon necropsy, multiple necrotic liver 
lesions were discovered. Scientists eventually traced the incident to moldy peanut meal 
originating from South America  [23]. Other fowl that can be affected by Turkey X 
disease include ducklings and pheasants. Younger poults ranging from 2 to 8 weeks are 
also susceptible [24].    
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Since those historic events, other animals have been assessed for AFB1 
susceptibility and have exhibited varying responses. The LD50 values determined from 
this work are a good predictor of toxicity, and also indicate the likelihood of cancer 
progression in each species. Initially, while carcinogenicity was the primary concern 
with AFB1, studies have also focused on delineating its association with 
immunosuppression, teratogenesis and other physiological effects.  Because of the high 
levels of phase I metabolizing enzymes, species such as rabbits, pheasants, ducks, 
turkeys and trout and other species are highly sensitive to AFB1. On the other hand, 
chickens, which have lower levels of phase I metabolizing enzymes are highly resistant 
to AFB1, and show minimal signs of aflatoxicosis up to 2.5 ppm  [25]. In general, 
species that possess high levels of glutathione-s-transferase (GST) are more resistant to 
aflatoxicosis. Human liver microsomes are only one-quarter efficient at activating AFB1 
when compared to rat microsomes at high concentrations. Mouse microsomes can 
efficiently create the AFB1 epoxide, but it is rapidly detoxified due to the efficient 
conjugation of the epoxide with GSH. Therefore, mice are less prone to 
hepatocarcinogenesis than other animals where this mechanism is not as efficient  [26].  
1.1.5 Aflatoxin immunosuppression  
Aflatoxin B1 can significantly alter the immune system. Controlled laboratory 
studies in animals have demonstrated that AFB1 immunosuppression greatly increases 
the risk of secondary infection  [27].  Young pigs exposed to 800 ppb AFB1 showed 
signs of immunosuppression after 25 days.  These pigs had depressed blood lymphocyte 
proliferation and oxidative radical burst was inhibited.  Additionally, in utero piglets 
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whose mothers were exposed to AFB1 had a decrease in cortical thymus lymphocytes 
and a decrease in thymus weight after exposure  [28, 29].  Weanling rats and adult rats, 
alike, have shown immune alterations after exposure toAFB1 [30]. Raisuddin et al. 1994 
described this toxicity. In the study, 5-6 week-old rats were fed 60 to 600 ppb AFB1 
every other day for 4 weeks. This had a substantial impact on cellular immunity, 
including LPS-induced lymphocyte proliferation, but did not affect humoral immunity. 
Aflatoxin B1 administered to rats intravenously over 2 wks negatively affected thymus 
and bone marrow cellularity, LPS-lymphocyte proliferation, phagocytic function of 
peritoneal macrophages and delayed hypersensitivity responses in mice exposed to 
AFB1, helper T cells as well as IL-2 levels decreased at  0.75 mg/kg  [31].  Aflatoxin B1 
negatively impacts the immune system by decreasing production of lymphokines and 
interfering with antigen processing by macrophages  [32, 33].  
In vitro studies have also demonstrated immune dysfunction in murine peritoneal 
macrophages following AFB1 exposure. A decrease in nitric oxide (NO) production and 
reactive oxygen intermediates (ROI) was demonstrated when in vitro cultures were 
treated with LPS. Proinflammatory cytokines produced from macrophages were also 
significantly reduced, including TNFα, IL-1 and IL-6  [34].  Low doses of AFB1 (0.05-
0.1 pg/mL) decreased phagocytosis and  bacteriocidal  activity against Candida albicans 
in human monocytes  [35], indicating increased disease susceptibility with AFB1 
exposure. Direct exposure to 20 pg AFB1 in chicken macrophages resulted in a 
significant reduction in substrate adherence (P=0.0007)  [24]. In the same study, lower 
doses (5-10 pg) caused a less dramatic decrease in substrate adherence (P=0.05). Five to 
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twenty pg/mL doses of AFB1 resulted in morphological alterations, cytoplasmic 
blebbing and nuclear disintegration, characteristic of cell damage. Aflatoxin B1 is also a 
notable pro-oxidant  [36]. When bovine neutrophils were evaluated for ROS production 
after AFB1 exposure, in vitro, O2
- production and MPO (myeloperoxidase) activity 
significantly decreased. When challenged with E.coli and S.aureus, phagocytic activity 
significantly decreased in AFB1-exposed neutrophils, compared to the controls. 
Broiler hens fed between 0.2 and 5 ppm AFB1 for 3 weeks demonstrated cell-
mediated immunity, humoral immunity and phagocytic cell compromise in their 
offspring  [37]. Turkeys, chickens and other livestock exposed to aflatoxin frequently 
result in economic losses for producers because of their reduced immunity and increased 
susceptibility to disease.  Low-level exposure to AFB1 over a long-period of time is 
known to enhance susceptibility to infection and tumorigenesis in many 
vertebrates  [38]. Sub-chronic exposure to AFB1 in chickens over an extended period of 
time has been known to contribute to increased disease susceptibility  [39]. In one study, 
chicks were fed chicks from 7-days old to 7 wks with 1 ppm AFB1, and the chicks were 
subsequently challenged with FAV-4 (fowl adenovirus serotype 4). There was a marked 
depletion of lymphocytes in all immune organs including the bursa, thymus, spleen and 
tonsils in AFB1-exposed chicks, compared to the control group. Furthermore, AFB1-
exposed chicks were  more adversely affected from  the FAV-4 virus than their control 
counterparts  [40].  
Metabolic studies in salmonid fishes including trout, coho salmon and others 
such as zebrafish and channel catfish have revealed the mechanism behind AFB1-
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induced toxicity. The aflatoxin B1-8,9 epoxide (AFBO) is the toxic intermediate that is 
responsible for causing DNA adduct formation in salmonid fish liver. Within the family 
of ray-finned fish, rainbow trout exhibit high sensitivity to AFB1, while coho salmon are 
fairly resistant  [41]. Sensitivity towards AFB1 in fish is due to the balance between 
phase I and phase II metabolizing enzymes. Salmon liver contains nearly 5 times less 
CYPLM2 (CYP2K1) when compared to trout liver  [42].  Glucuronidation (phase II 
metabolism) and glutathione conjugates in trout are often negligible, as compared to 
other salmonids and mammals  [43, 44]. This means that because phase I metabolism is 
extremely efficient, AFBO is readily formed. However, because of the lack of phase II 
metabolizing enzymes, limited detoxification occurs and the epoxide forms the DNA 
adduct more easily than in other species. 
1.1.6 Aflatoxin decontamination 
Decontamination of aflatoxins by chemical means or by processing has been 
explored in years past. There are a number of factors that are considered regarding 
aflatoxin decontamination: 1) removing, destroying or inactivating the mycotoxin, 2) 
retaining the nutritive value of the feedstuff 3) limiting or not leaving any toxic residue 
4) not altering the properties of the product and 5) destroying the fungal spores that may 
produce additional mycotoxins during the storage process In a study by Cole et al. 
(1989), it was demonstrated that removing  mold damaged kernels can result in a 40-
80% reduction in AFB1  [45]. Additionally, Lopez-Garcia et al. (1998)  found that 
flotation and density segregation were somewhat effective for contaminated corn and 
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peanuts however AFB1 residues still remained The food industry has investigated this 
method to decontaminate peanuts that are used for peanut butter  [46].  
 Aflatoxins are relatively heat stable. Processes such as boiling and autoclaving 
are not entirely effective in eliminating AFB1 from feed components. Fermentation 
results in a 70-80% reduction in AFB1  contaminants in different grains  [47]. Gamma-
irradiation has been attempted and did not degrade AFB1 in peanut meal  [48]. However, 
e-beam irradiation resulted in a 75.49% decrease in AFB1 contamination in coconut 
agar  [49].    
Nixtamalization is the process of using an alkaline solution to prepare maize or 
grains, such as the production of tortillas.  Aflatoxin B1 is susceptible to alkaline pH and 
can be degraded at the lactone ring using this process [51, 52]. The resulting reaction at 
equilibrium produces two less toxic metabolites, ; however, the reaction is reversible at 
intermediate stages and can result in reformation of parent AFB1 under acidic conditions  
found in the stomach. 
Human and animal intervention strategies have also been explored. However, 
several of these post-harvest strategies, such as Oltipraz, chlorophyllin, isothiocyanates 
and triterpenoids are not realistic for large-scale implementation in livestock and 
commercial farms due to their high cost. Intervention strategies that are inexpensive, 
effective, and safe are needed  [50].  
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1.2 Aquaculture 
1.2.1 Aquaculture industry 
Aflatoxins can affect several livestock species including turkeys, chickens, pigs 
and fish. There are currently over 123 finfish species that are cultured worldwide.  
Aquaculture is a $50 billion industry and the largest growing food sector due to 
decreases in wildstock and overfishing  [51].  Due to the growing global population and 
associated strain on the food supply, aquaculture is expected to become increasingly 
important over the next century. Fishery products are some of the most traded food 
commodities globally. Subsequently, demand is expected to continue rising as 
aquaculture production expands (Fig. 2).  In the next decade, production of aquaculture 
products is expected to exceed total production of beef, pork or chicken [52].  Recently, 
the United Nations Conference on Sustainable Development, also known as Rio+20, 
facilitated discussion of world hunger issues and methods to improve food security, 
while using fewer natural resources. The focus on improving small-scale aquaculture 
operation sustainability to promote poverty eradication is pertinent to both the domestic 
and international communities, especially in countries throughout sub-Saharan Africa, 
where food shortages are common.  Promoting sustainable fish farming can promote 
economic stewardship and environmental responsibility  [53].   
In 2010 alone, aquaculture and capture fisheries produced 148 million tons of 
fish, 128 million of which were utilized as food for people.  Sustained increases in fish 
production have occurred as a result of improved distribution channels and the farmed 
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Figure 2. Aquaculture production growth and total production value according to geographical region  [54]. 
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fish supply has grown dramatically with a rate of 3.2% per year.  Consumption of fish 
has increased from 9.9 kg in the 1960s to 18.4 kg in 2009  [55].  
China’s utilization of the farm-raised fish has a substantial effect worldwide and 
has been responsible for the greatest increase in fish production  [56]. China’s 
production grew from about 7 percent in 1961 to 35% in 2010.  Likewise, fish 
consumption in China has risen to approximately 31.9 kg in 2009, and has increased 6% 
each year for the last 10 years.  In 2009, 16.6% of fish accounted for the world’s intake 
of animal protein and 6.5% of all protein consumed globally.  Nearly 3 billion people 
consume fish worldwide and fish account for 20% of total intake of animal protein  [57, 
58].  
Freshwater sources account for 60% of world aquaculture production, despite the 
fact that only 3% of the planet’s water is fresh  [54]. Brackish water aquaculture is also 
growing in popularity, especially in regions such as Africa and Latin America. Because 
of increasing pressure on freshwater supplies, future aquaculture development is 
expected to utilize brackish water more frequently.  The most widely farmed fish are 
salmon, carp, tilapia, sea bass, catfish and cod. Red drum is another commercially 
important species and is farmed in Ecuador, Israel the Gulf Coast of the United States 
and parts of China  [59]. Red drum thrive in brackish water and farming them can 
alleviate some of the strain on the freshwater aquaculture industry  [60].  
1.2.2 Fish immunology 
The fish immune system is similar to other vertebrates and can be divided into 
two categories: the innate immune system, and the adaptive immune system. The innate 
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immune system is non-specific and is considered the “first line of defense” (Fig. 3). It 
consists of macrophages, neutrophils, mast cells, basophils and natural killer cells. 
Conversely, the adaptive immune system is specific and is responsible for 
immunological memory (recognition of a previously encountered pathogen). Major cells 
of the adaptive immune system include T and B cells. Dendritic cells are classified as 
part of both the innate and adaptive immune system.  
   Because fish are free-living organisms during early embryogenesis, they rely 
more on their innate immune system than mammalian species  [61]. Innate immunity has 
three components: the mucosal barrier, the humoral parameters and the cellular 
components. An immune response typically involves all three components.  
Lysozyme is a bacteriolytic enzyme that is one of several humoral parameters 
and is present in serum, secretions, and mucous membranes. The kidney and intestine 
have the highest concentrations of lysozyme  [62, 63]. 
Protease inhibitors such as anti-trypsin are also present in the serum and other 
fluids  [64]. These molecules can promote the degradation of proteolytic enzyme-
secreting bacteria  [65]. Assessment of anti-trypsin is a good measure of humoral 
immune function. Other processes in the innate immune system include neutrophil and 
macrophage phagocytosis and pinocytosis. These cells engulf pathogens by producing 
reactive oxygen species (ROS) such as O2
-
, H2O2, and NO
-  [66]. These compounds are 
produced both intracellularly and extracellularly and kill bacteria by breaking down their 
cell walls. 
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Figure 3. Components of the innate immune system in fish. Includes  a series of cytokines, chemokines, ROS, lysozyme and 
serum components. 
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1.2.3 Farmed fish feed, fish nutrition, and potential contaminants 
Immunity in fish can be affected by nutritional factors in their feed as well as 
naturally occurring and anthropogenic contaminants. There are two major categories of 
nutrients for fish: 1) macronutrients, including carbohydrates, lipids and proteins and 2) 
micronutrients, consisting of vitamins and minerals. Typically, proteins in commercial 
feed contain amino acids from both animal and plant sources.  Protein is also the most 
expensive component in fish feed, and excess protein in the feed is not economically 
feasible and also causes excess nitrogen build up in the water. Herbivorous and 
omnivorous fish consume about 25-30% protein in the diet, however carnivorous fish 
require more (approximately 40-55% protein). There are ten essential amino acids that 
are included in commercial fish diets including arginine, histidine, isoleucine, leucine, 
lysine, methionine, phenylalanine, threonine, tryptophan and valine [67].   
Lipids are the next group of essential nutrients in fish feed. Essential fatty acids 
(EFAs) typically provide fish with long-chain unsaturated fatty acids such as linoleic 
(18:3 n-3 and linoleic acids 18:2 n-2). Dietary lipids are precursors to steroids, hormones 
and prostaglandins. Prostaglandins are important for intestinal absorption of fat-soluble 
vitamins. Lipids and lipid-soluble products, including certain toxins, can bioaccumulate 
in the muscle and fat.  
In order to meet all of the necessary physiological requirements of growing fish, 
all essential nutrients must be present in the feed for growth and reproduction. While 
progress has been made in the last half-century in fish nutrition, quantitative
18 
 
requirements for nutrients and limitations of contaminants in fish feed have not been 
well-established. Recently, nutritional requirements for well-known commercial species 
such as rainbow trout, Pacific salmon, channel catfish, tilapia and carp have been 
established due to their frequent farming in the industry  [68].  
Some species, such as tilapia can be fed either an herbivorous or omnivorous 
diet, and are a much sturdier species than rainbow trout, which require highly monitored 
cultivation. Aquaculture feed is composed of a series of ingredients to meet all of the 
nutritional requirements of a specific fish species.  Red drum, for example, is a 
carnivorous species and therefore need a higher percentage of protein in the feed than 
tilapia. Excess intake of certain nutrients can potentially harm the fish, causing nutrient 
build-up in the liver and fat tissues. For example, fat-soluble vitamins such as vitamin A 
or trace elements, such as copper can be toxic in excess  [69]. Deficiencies in primary 
essential nutrients and exposure to anti-nutrients might contribute to disease 
development, survival rate, integrity of the skin, liver, and other organs or the 
composition of tissues in the body  [70].  
There are other physiological factors that affect metabolism in fish such as 
environmental temperature. Fish are poikilothermic, meaning that their metabolic rate 
and body temperature is determined by the water temperature. Drastic changes in 
environmental temperature can dramatically affect energy expenditure and food and 
nutrient intake. Fish are very efficient at utilizing fats and protein over carbohydrates, 
and can absorb minerals and/or potential contaminants through their skin and gills. 
Because fish are primitive vertebrates, they also possess anatomical features important in 
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bioavailability and metabolism that mammalian species do not. They have distinguishing 
features such as a lack of mandibular teeth and non-differentiated small and large 
intestine. Fish intestinal cells can also absorb molecules via pinocytosis  [71].  
Food consumption in farm-raised fish can be affected by daily, annual and lunar 
rhythms. Because of this, most aquaculture systems provide the fish with diurnal lighting 
to maintain their natural circadian rhythms. In a farmed-fish setting, fish are fed at their 
optimal feeding time to promote efficient feeding and prevent waste. In addition to 
circadian rhythms, other factors affect feed consumption. Due to the piscine gustatory 
system, fish are able to discriminate between high-quality and low-quality feed that is 
either rancid or was stored improperly. Behavioral effects such as feed refusal are 
evident when poor-quality feed is administered  [72].  
Fish can bioconcentrate or bioaccumulate contaminants either through their food 
or through their gills and skin. The rate that contaminants are accumulated is based on 
the age, size, species, and nutrition of the fish  [73, 74]. The composition of fish feed 
includes fish oil and fish meal as well as organochlorine residues that have been 
frequently detected in these components. Salmon feed can contain up to 30% fish oil and 
50% fish meal. Other contaminants enter fish as a result of airborne industrial chemical 
release  [75]. Fatty, carnivorous fish that are high on the food web are more likely to 
contain high contaminant loads.  
With the advent of plant-based feed alternatives in aquaculture feeds such as 
cottonseed, soybean meal, corn meal, and peanut meal, the unintentional addition of 
anti-nutritional organic compounds is common. Well-known antinutritional ingredients 
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include protease inhibitors, phytates, glucosinolates, saponins and tannins, 
oligosaccharides, mycotoxins, phytoestrogens, and antivitamins. There are four 
subcategories of antinutrients: 1) factors that affect protein utilization and digestion 2) 
antivitamins 3) factors that inhibit mineral utilization and 4) other toxic substances 
including mycotoxins, phytoestrogens, nitrates, alkaloids, and saponins  [76].  
1.2.4 Aflatoxin in aquaculture  
Fishmeal has typically been the most prevalent protein source in feeds; however, 
due to cost, fish farmers are seeking alternative sources from plants. Increased usage of 
plant materials in fish feed may result in an increased prevalence of mycotoxin 
contamination. Mycotoxin exposure is known to cause a vast array of pathological 
effects in fish and fish cells (Table 1). Evidence continues to mount regarding the threat 
they pose to farm-raised fish. While aflatoxins have been studied in multiple species 
such as turkeys, chickens, ducks, swine, rodents and more recently humans, they were 
first discovered to be extremely toxic in a farm-raised fish species, rainbow trout 
(Oncorhynchus mykiss), due to their development of AFB1-induced liver tumors  [77, 
78]. Other researchers have reported that chronic dietary exposure to <1 ppb AFB1 can 
cause hepatomas in rainbow trout  [79, 80]. Warm-water fish tend to demonstrate more 
resistance to aflatoxins than cold-water fish like rainbow trout. Channel catfish 
(Ictaruslus punctatus) fed between 2,154 ppb up to 10,000 ppb AFB1 exhibited 
decreases in weight gain, increases in liver histopathology, necrotic hepatocytes and 
infiltrating macrophages in the gastrointestinal tract  [81]. 
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Table 1. Mycotoxin-aquaculture studies   
Species Mycotoxin Effects Citation 
Sea bass (Dicentrarchus 
labrax L) 
AFB1 Five ppb deposited in fillet, 
increased levels of 
transaminases and alkaline 
phosphatase activities, and 
significantly decreased 
plasma protein 
El-Sayed and 
Khalil 2009 [82] 
Tilapia (Oreochromis 
niloticus × O. aureus) 
AFB1 Decreased growth, HSI and 
lipid content, increased 
hepatic disorder, ATL, 
CYP450 1A 
Deng et al. 
2010 [83] 
Tilapia (Oreochromis 
niloticus L.) 
AFB1 Caused cataracts, blindness, 
weight loss, fin and tail rot, 
abnormal swimming 
Cagauan et al. 
2004 [84] 
Indian major carp 
(Labeo rohita) 
AFB1 Reduced total protein, 
globulin, NBT, bactericidal 
activities, bacterial 
agglutination titer 
Sahoo and 
Mukherjee 
2001 [85] 
Catfish (Ictalurus 
punctatus) 
AFB1 Increased immature blood 
cells, excessive amounts of 
iron in mucosal epithelium, 
necrotic glands in the 
stomach with infiltrating 
macrophages 
Jantrarotai and 
Lovell 
1990 [81] 
Rainbow trout (Salmo 
gairdneri) 
AFB1 Loss of B-cell memory Arkoosh and 
Kaattari 
2006 [86] 
Guppies (Lebistes 
reticulatus) 
AFB1 Development of hepatic 
tumors, hyperplastic nodules, 
kidney lesions 
Sato et al. 
1972 [87] 
Walleye (Sander 
vitreus) 
AFB1 Aflatoxins up to 20 ppb 
detected in the musculature, 
hepatic histopathological 
lesions 
Hussain et al. 
1993 [88] 
Asian tiger shrimp 
(Penaeus monodon) 
AFB1 Poor growth rate, high 
susceptibility to shell 
diseases 
Bautista et al. 
2006 [89] 
Juvenile hybrid 
sturgeon (Acipenser 
ruthenus ♂ × A. baeri♀) 
AFB1 Nuclear hyptertrophy, 
hyperchromasia, focal 
hepatocyte necrosis, biliary 
hyperplasia, inflammation in 
the liver, 10 ppb AFB1 
accumulation in the muscle 
Raghavan et al. 
2009 [90] 
Gibel carp (Carassius 
auratus gibeli) 
AFB1 Decreased specific growth 
rate and feed efficiency 
Han et al. 
2010 [91] 
RTL W-1 trout cell line Deoxynevalenol 
(DON) 
Biphasic cellular response, 
decreased ROS production 
Pietsch et. al 
2011 [92] 
Zebrafish (Danio rerio) Zearalenone (ZEA) Reduced spawning 
frequency, increased plasma 
vitellogenin in male 
zebrafish 
Schwartz et al. 
2010  [93] 
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Table 1. Continued    
Species Mycotoxins Effects Citation 
Rainbow trout 
(Oncorhynchus mykiss) 
Fumonisin B1 (FB1) 
and aflatoxin B1 
(AFB1) 
FB1 promoted AFB1 liver 
tumors 
Carlson et al. 
2001 [94] 
Catfish (Ictalurus 
punctatus) 
T2 toxin and 
ochratoxin (OTA) 
Significantly higher 
mortality compared to 
control when challenged 
with pathogen, Edwardsiella 
ictaluri 
Manning et al. 
2004 [95] 
Sea bass (Dicentrarchus 
labrax L) 
OTA Fin erosion, behavioral 
changes, nervous and 
respiratory problems, 
hemorrhagic patches, 
congestion of kidney and 
liver 
El-Sayed et al. 
2009 [96] 
 
 
Another species, Oreochromis niloticus (Nile tilapia), has been assessed for 
AFB1 susceptibility in multiple studies [83, 97, 98].  In these studies, it was determined 
that Nile tilapia are susceptible to AFB1 at concentrations between 1.5 and 1.6 ppm with 
the development of hepatic lesions, weight loss, immunosuppression and clouding of the 
eyes. However, while adult tilapia are relatively resistant, young fingerlings are more 
sensitive and have significantly reduced survival when exposed. The same age-
dependent sensitivity is also noted in other species. “Yellow disease,” which is 
characterized by yellowing of the body and skin, fin and tail rot, cataracts, abnormal 
motility and reduced feed intake is seen in tilapia as a consequence of AFB1 
exposure  [84]. Carp fed 2.5 mg AFB1/kg body weight over a period of 9 mo. had lesions 
in the liver, severely damaged kidney tissue and pathology in the gastrointestinal tract, 
heart and brain  [77]. Sea bass exposed to 1.8 mg/kg body wt. AFB1 for 42 d. resulted in 
5 ppb AFB1 accumulation in the muscle [82]. Therefore, one can conclude that AFB1-
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exposure can exert a bioaccumulative effect throughout the food web and humans who 
consume farm-raised fish are at risk for AFB1 exposure. 
Immunosuppressive effects arising as a result of AFB1 exposure have also been 
cited in aquaculture studies. When trout are exposed as embryos to AFB1, they suffer 
long-term immunodeficiency  [99]. In this study, rainbow trout were exposed to 0.5 mg 
AFB1 for 30 min., after which leukocytes were cultured and mitogens were tested after 
LPS stimulation. Anterior kidney immunoglobulin production was roughly 2/3 of control 
levels in AFB1-exposed embryos. Nile tilapia exhibit reduced macrophage phagocytic 
activity after exposure to 200 ppb AFB1  [100]. Other species such as the Labeo rohita 
experience suppressed serum bactericidal activity, neutrophil function and globulin 
levels after AFB1 exposure. Aflatoxin injection in this species at 1.25 mg/kg body 
weight resulted in lymphocytolysis  [85].  
Although aflatoxins are known to adversely affect several types of fish,   they 
have not been thoroughly investigated in all aquaculture species.  More information is 
needed on aflatoxin contamination in feeds and fishmeals, toxicological effects induced 
in farmed aquatic species, and DNA damage in fish genomes and  its impact on 
carcinogenesis  [13]. Aflatoxin contamination has been detected in aquaculture feeds and 
occurs in several feed components including soybean, peanuts, maize, rice and 
menhaden meal. A study carried out in Egypt detected aflatoxin levels exceeding 1,000 
ppb in fish feed  [101]. Others in Portugal determined that out of 35 samples of fish feed, 
over 40% tested positive for AFB1  [102]. Another investigation quantified aflatoxin and 
fumonisin levels from tilapia feed in Nayarit, Mexico and determined that 63% of 
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samples tested positive for aflatoxins, however all levels were below the European 
maximum for animal feed  [103]. In the Philippines, researchers determined that shrimp 
feed contained AFB1 levels from 0 to 120 ppb  [89]. One study from Brazil analyzing 60 
fish feed samples from Rio de Janeiro State resulted in 35% of the samples testing 
positive for A. flavus, and 55% of samples testing positive for AFB1 
contamination  [104]. Animal and aquaculture feeds are often co-contaminated with 
AFB1 and other mycotoxins, including fumonisin B1 (FB1), ochratoxin and 
zearalenone  [105].  
1.3 Therapeutic clays 
1.3.1 Clays in ancient medicine: a historical perspective 
Geomaterials such as soils and clays can have major beneficial impacts on 
human health. Clays are aluminosilicates mainly composed of oxygen, silicon and 
aluminum, with traces of Na, K, Mg and Ca. Geophagy is described as the “deliberate 
consumption of earth, soil or clay”, a practice that has existed worldwide for thousands 
of years. Geophagy is well-documented in southern parts of the United States, Africa, 
and Asia and is considered “culturally acceptable”  [106]. Pregnant women in 
developing countries  are known to consume earth, especially during famine  [107]. 
Early Greek and Roman medical textbooks document the practice of geophagia, and 
early reports indicate an association between geophagia and alleviating anemia  [108]. 
“Hippocrates and Aristotle both wrote about medicinal clays and also gave classification 
to several clays based on their geographic origin such as Terra Samia, T. Sigillata, T. 
Lemnia, T. Cimolia, T. Sonoptica, T. Eretia, and T. Negra    [109, 110].  
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1.3.2 Clay as an aflatoxin intervention 
Because of AFB1-related morbidity and mortality in multiple species, there is a 
need for intervention strategies to reduce AFB1 exposure. There are several methods of 
controlling aflatoxin exposure, including food and feed processing, microbial 
inactivation, dietary strategies, chemical degradation or chemisorption with clay. 
Adsorbents including zeolites, silicates and organoclays have been evaluated, however 
smectite clay has been the most effective in vitro and has demonstrated tight binding 
complexes with the aflatoxins  [111]. These complexes are stable from pH 2-10 in vitro 
as well as at temperatures of 25 and 37ᵒ C. Less than 10% of parent AFB1 can be 
dissociated from the complex by a series of solvents. Ellis et al. (2000) determined that a 
minimal level of smectite (1%) was capable of removing 44% and 52% of AFM1 in 
cattle and goat milk samples, respectively. Two-percent bentonite clay inclusion has 
been used in rainbow trout feed to reduce toxicity resulting from 20 ppb AFB1 exposure 
and significantly decreased liver cancer rates  [112].  Dosage of clay-based additives in 
animal feeds to prevent aflatoxin toxicity has varied substantially. In pigs dosed between 
500 and 800 ppb AFB1, 1 and 2% Ca-bentonite was just as effective as 0.5% in reducing 
AFB1 serum levels  [113]. Consumption of clay-based minerals has resulted in decreased 
bioavailability of AFB1 to target organs such as the liver, muscle and blood  [114].   
Originally used as an anti-caking agent in animal feeds, NovaSil (NS) is a 
calcium-montmorillonite clay that has demonstrated AFB1-binding ability both in vitro 
and in vivo. Broiler and leg-horn chickens were rescued with NS from the effects of 
exposure to 7500 ppb AFB1   [115]. Importantly, NovaSil has been used safely and 
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efficaciously in humans in a number of clinical trials to reduce exposure from both AFB1 
and fumonisin (FB1), both in the United States and in Africa  [116, 117]. NovaSil does 
not significantly alter serum levels of vitamins and minerals including, calcium, vitamin 
A and iron in rodents or human subjects  [118]. NovaSil has also been tested for its 
ability to reduce transfer of AFM1 to milk following ingestion of aflatoxins in 
cows  [119].  In that study, cows were fed diets contaminated with 200 μg AFB1/kg or 
0.5% NS+200 μg/kg AFB1 for 7 days. During the final 7 days, NS was removed from 
the diet. The presence of 0.5% NS decreased AFM1 milk levels by an average of 0.44 
µg/L (44% reduction). 
There are two types of NovaSil currently available for animal and human use. 
The original parent compound, NovaSil Plus (NSP), has been frequently used in animal 
feeds. More recently, a more refined version, Uniform Particle Size NovaSil (UPSN) has 
been developed to minimize the content of particles >100 µm. This was developed to 
decrease batch to batch differences and increase palatability.  
1.3.3 Smectite clays 
Smectite clays are a group of silicates with an expandable interlayer and several 
structural features that affect surface charge. Montmorillonite is one sub category of 
smectite clays and is characterized by a 2:1 dioctahedral structure (Fig. 4). The chemical 
formula for montmorillonite is (Na,Ca)0.33(Al,Mg)2(Si4O10)(OH)2*nH2O. In geological 
features over time, isomorphic substitution can cause many elements, including those 
with a less positive charge, to substitute into these sites, thereby causing an overall 
negative charge in the interlayer. For example, Mg2+ can substitute for Al
3+
 in octahedral 
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Figure 4. Molecular schematic of smectite. A) Dioctahedral sheet B) tetrahedral sheet C) structural schematic of smectite 
clay [120]. 
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sheets and Al3+ can substitute for Si4+ in tetrahedral sheets. This exchange (isomorphic 
substitution) is responsible for the interlayer charge. Soil smectite usually contains Ca2+ 
and Mg2+ that can be replaced by Al3+. The montmorillonite crystal lattice consists of 
layers that are approximately 1-2 nm thick. There is one octahedral sheet sandwiched 
between two tetrahedral sheets, similar to talc or mica. Each tetrahedron consists of four 
oxygen molecules and either an Al or Si. Each octahedron contains Al, Fe or Mg 
surrounded by four oxygen molecules and two –OH groups.  These layers create stacks 
and the opening between each layer is referred to as  the interlayer [120].   
Scanning electron microscopy (SEM) is frequently used to characterize smectite 
clays without damaging the structure. Many montmorillonites display a honeycombed 
polygonal pattern, though some exhibit a thin film and flake-like structure, such as 
granordiorite  [121]. The cation exchange capacity (CEC) is approximately 110 cmolc 
kg-1 for soil smectite. Some high-charge smectites possess higher potassium levels and 
are therefore similar to vermiculite. The edges of smectite can also contribute to the 
CEC. Approximately 5 cmolc kg
-1 of the total CEC is attributed to the edge charge.  
Isomorphic substitution causing a permanent charge from OH bonds and broken O 
bonds is called “pH-dependent charge.” Typically, swelling and shrinking have also 
been characteristics of clays and smectite. In particular, crystalline swelling occurs when 
H2O molecules are sequestered between the interlayers. Water molecules interstratifying 
several layers or in different packing arrangements can influence the swelling range of 
the crystalline structure  [122]. Forces of attraction and repulsion can influence 
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crystalline swelling and coulombic attraction between the negative and positive surface 
charge sites causing electrostatic attraction to molecules.  
X-ray diffraction (XRD) is a way to characterize crystalline materials. In XRD, 
an x-ray beam hits the material and based on the incident angle, characteristics such as 
the distance between planes (the d-spacing), can be determined. Heat and humidity can 
both affect smectite and these factors must be controlled when analyzing smectite with 
XRD. X-ray diffraction will result in a 1 nm peak for smectite that can collapse slightly 
at 110 degrees C  [123].  
1.3.4 Clays in intestinal illness 
One potential application for smectite clays is to treat intestinal illness. The first 
known book that documented the use of “stones” for medicinal benefits was called De 
Materia Medica and mentioned pharmaceutical uses of clays especially for stomach and 
intestinal illness. Clays that are used frequently for pharmaceutical use include smectites, 
palygorskite, kaolinite and talc (Table 2). Clay minerals that have been used specifically 
for gastrointestinal complaints include palygorskite and kaolinite. Clays have been cited 
to coat the gastric wall and absorb toxins, bacteria and viruses  [124, 125]. Binding 
studies performed with Salmonella enteriditis indicated that a cetylpyridinium-
exchanged montmorillonite clay was able to reduce bacterial counts by 98%.  In vitro, 
montmorillonite clay sorbed rotavirus and coronavirus, two viruses that cause intestinal 
symptoms  [126]. Additionally, they have been known to alter tight junctions between 
cells, thereby improving cellular adhesion resulting in enhanced pancreas and intestinal 
enzyme activities and mucosal integrity [127]. 
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Table 2. Clay-based supplementation in aquaculture feed  
Species Clay  Effects Citation 
Eastern oyster (Crassostrea virginica) kaolinite  kaolinite adsorbed organic 
matter from feed 
Urban et al. 1992 [128] 
Oyster (Crussostrea gigus)  kaolinite, illite, 
montmorillonite 
kaolinite and 
montmorillonite particles 
(3-4um) increased 
ingestion 
Sornin et al. 1988 [129] 
European seabass (Dicentrarchus labrax) Zeolite up to 20% inclusion did 
not affect protein 
digestibility or growth 
performance 
Dias et al. 1998 [130] 
Nile tilapia (Oreochromis niloticus) Cu2+ exchanged 
montmorillonite 
antibacterial activity, 
protected intestinal 
mucosa from pathogens, 
improved growth 
performance 
Hu et al. 2007 [131] 
Nile tilapia (Oreochromis niloticus) montmorillonite montmorillonite reduced 
Pb accumulation in 
kidney, intestine, bone, 
stomach, gill, liver, spleen 
Dai et al. 2010 [132] 
Mozambique tilapia (Oreochromis 
mossambicus) 
Zeolite reduced Cd levels in fish  Sampath 1999 [133] 
Multiple farmed fish species Bentonite reduced AFB1 levels in 
fish feed 
Winfree and Alred 
1992 [134] 
Nile tilapia (Oreochromis niloticus) montmorillonite reduced 
sterigomatocystin-related 
genotoxicity  
Abdel-Wahhab et al. 
2005 [135] 
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Diarrhea, which can be caused by a variety of viruses and bacteria, is defined as the 
passage of three or more loose stools per day. Diarrhea can also be caused by chronic 
health conditions, defective intestinal absorption, allergies and food poisoning. Diarrhea 
can be life threatening especially for the very young, the malnourished, or those with 
impaired immune systems. The WHO has estimated that more than 1 in 10 children die 
from diarrhea each year, which is approximately 800,000 children [136]. Only 44% of 
these children with diarrhea are able to receive medical treatment  [137]. 
Most anti-diarrheal agents involve the absorption of excess water from the large 
intestine, thereby resulting in more compact feces.  Calcium smectites have been used to 
treat diarrhea and are excreted completely in the feces rather than being absorbed.  These 
clays can either be administered directly into the food or administered via tablet or 
capsule to treat diarrhea. Additionally, Ca2+ in the interlayer of the clay can exchange for 
other divalent ions. 
Clinical trials and animal studies alike have extensively tested the efficacy, 
safety, tolerability and palatability of clays for health supplementation and found little to 
no adverse side effects  [114] (Table 3).  One study in Italy with 804 children examined 
the efficacy of a dioctahedral smectite (DS, or diosmectite) clay for treatment of acute 
diarrhea  [138]. Smectite supplementation was found to reduce the duration and 
frequency of diarrhea, in addition to improving stool consistency. Another similar study 
in India examined DS in 117 children with watery diarrhea  [139]. There were similar 
findings in terms of reduced duration of diarrhea, and no adverse side effects from
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Table 3. Gastroenterology studies with clay 
Condition  Treatment  Results Citation 
Gastroenteritis Smectite Reduced duration of 
diarrhea and prevented a 
prolonged course 
Guarino et al. 2001 [138] 
Rotavirus and 
coronavirus (in 
vitro)  
Smectite Clay sorbed between 77-
99% of viral load 
Clark et al. 1998 [126] 
Infectious 
diarrhea  
Smectite Shortened diarrhea 
duration and frequency of 
liquid stools 
Madkour et al. 1993 [140] 
Infectious 
diarrhea  
Smectite  Successfully used with 
rehydration therapy to treat 
diarrhea  
Szajewska et al. 2006 [141] 
Acute 
gastroenteritis 
Smectite Duration of diarrhea 
reduced and no effect on 
electrolyte concentrations 
Narkeviciute et al. 2002 [142] 
Irritable bowel 
syndrome 
(Diarrhea) 
Diosmectite  Diosmectite was well-
tolerated and alleviated 
pain-related symptoms 
Chang et al. 2007 [143] 
Chronic 
functional 
diarrhea 
Smectite Decreased frequency of 
daily bowel movements 
and  
Yao-Zon et al. 2004 [144] 
Acute diarrhea Smectite Shortened diarrhea 
duration and improved 
dehydration 
Yen et al. 2006 [145] 
Acute watery 
diarrhea 
Diosmectite  Reduced duration of 
diarrhea and prevented a 
prolonged course, thereby 
possibly reducing costs 
Mujawar et al. 2012 [139] 
Clostridium 
difficile toxins  
(in vitro) 
Ditrioctahedral 
smectite 
Neutralized toxins A and B 
from Clostridium difficile  
Weese et al. 2002 [146] 
Post-operative 
diarrhea in horses 
Ditrioctahedral 
smectite 
Reduced occurrence of 
diarrhea immediately 
following surgery 
Hassel et al. 2009 [147] 
Acute diarrhea  Diosmectite  Diosmectite with 
rehydration shortened the 
course of illness 
Lexomboon et al. 1994 [148] 
Enteric diarrhea 
in weanling pigs 
Palygorskite Protective effect against 
diarrheal infection and 
improved intestinal wall 
barrier 
Zhang et al. 2013 [149] 
Diarrhea in 
weanling pigs 
Kaolinite Alleviated symptoms Rivera et al. 1978 [150] 
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administration of the clay, despite the relatively high dose administered (6g/day). 
Another 2006 study evaluated the efficacy of DS clay to alleviate diarrhea- predominant 
irritable bowel syndrome  [143]. One-hundred and four patients between the ages of 20 
and 80 who had reported diarrheal episodes prior to the study were subject to DS 
treatment. This treatment consisted of a dose equal to one g 3 times a day for 8 weeks. 
Another study involving cases of constipation-predominant IBS reported that beidellite 
(a montmorillonite clay) was able to adsorb gas and led to modification of luminal 
chemical changes  [151]. Patients experienced a decrease in IBS symptoms, compared to 
the placebo. Additionally, pain and discomfort was significantly improved. Diosmectites 
have been used in studies to treat functional bowel disorders, in which they alleviated 
abdominal swelling and bloating and provided an alternative to dietary restriction  [152].  
A few studies have been published regarding the use of diosmectites as therapy 
for IBD [153]. In a short-term investigation, the anti-inflammatory effects of smectite 
were observed in a rat colitis model. Expression of MUC2, a gene that encodes for a 
mucin-secreting protein, was upregulated in colitis-induced mice administered smectite, 
suggesting that mucin production increased. This study determined that colonic IL-1β 
was reduced, the severity of diarrhea decreased, and histopathological findings 
diminished with clay supplementation. There was also a marked decrease in diarrhea and 
reduction of nitric oxide synthase, a proinflammatory mediator. Although long-term clay 
ingestion has not been evaluated thus far, clinical study results indicate that a low-dose 
clay regimen is safe and tolerable  [116, 154]. 
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1.3.5 Clay-bacterial interactions 
Some studies have documented clay-bacterial interactions. In soil environments, 
clays and bacteria can form “hutches” or aggregates that house bacteria. Lucnsdorf et al. 
(2000) determined Pseudomonas putida bacteria can colonize the surface of 
montmorillonite clay structures, as indicated through scanning electron 
microscopy  [155]. However, 88.7% were readily desorbed, suggesting that weak, non-
electrostatic forces such as hydrogen bonding were involved in the sorption process. 
Montmorillonite (Fig. 5) itself does not possess anti-bacterial properties, but some 
investigators have attempted to exchange ions in the clay for other ions that possess anti-
bacterial properties. Hu et al. (2005) exchanged copper onto montmorillonite and 
examined its effects on E. coli 88. Bacterial suspensions were prepared and harvested. 
Antibacterial activity was assayed by using Ca-MMT, Na-MMT, Cu-Ca-MMT and Cu-
Na-MMT and the percent reduction was further calculated. The authors reported that the 
antibacterial activity of Cu-MMT was not affected by pH. Furthermore, copper was 
found to be exchanged in the interlayer when the pH was above 4.5 by entering the 
ditrigonal hole in the octrahedral sheets  [131]. 
Another study examined the effect of montmorillonite on growth performance 
and fecal microflora in weaning pigs subject to zearalenone exposure [156]. In this work, 
Lactobacillus counts increased while Escherichia coli counts decreased, regardless of 
the inclusion rate of montmorillonite. Lactobacillus is typically seen as “beneficial” 
bacteria and E. coli more pathogenic, however, the entire microbiome needs to be 
considered when assessing relative proportions of bacteria. Montmorillonites have
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B) A) 
Figure 5. Structure of NovaSil (NS) and AFB1 
NovaSil,  calcium montmorillonite clay demonstrating oxygens (red), silica (yellow) and 
aluminum (blue) composing the 2:1 dioctrahedral structure as well as the interlayer space between 
each layer (Fig 2A). Structure of aflatoxin B1 (AFB1) (Fig 2B). 
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demonstrated antibacterial ability by altering bacterial cell membrane 
permeability  [157]. Montmorillonite supplementation also significantly increased 
intestinal villus height and villus height:crypt depth ratio in the jejunum of young 
pigs  [158]. Xia et al. 2005 challenged weanling pigs with E. coli and examined the 
effect on the intestinal barrier and bacterial translocation from the intestinal lumen. 
When intestinal barrier function is reduced, enteric pathogens migrate more readily from 
the lumen to the lymph nodes. This study found that E.coli increased bacterial 
translocation, and smectite supplementation reduced translocation [159]. In vitro 
research has shown that smectite clays have the capability of binding bacteria and 
bacterial toxins, such as Clostridium perfringens  [160]. To date, there have been no 
molecular-phylogenetic studies to characterize the intestinal microbiome in animals 
consuming dietary clay.   
While microbiology was once entirely culture-dependent, the field has been 
revolutionized by next generation sequencing. Next generation sequencing (NGS) is the 
latest method of phylogenetic characterization for bacterial groups. One of the first high-
throughput sequencing methods (pyrosequencing-454) was introduced in 2005 and was 
then replaced with Illumina Sequencing in 2007. With NGS, bases of fragmented DNA 
are identified using emitted signals as DNA is resynthesized from the template strand. 
These reactions take place in a forward and reverse fashion and result in readings that 
are thousands of sequences deep. The sequences are then compared to a microbial 
reference database to determine phylogenetic analysis using QIIME software. Other 
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methods of microbial sequences are available, but Illumina (Solex) sequences is 
currently the most widespread  [161].   
There are two predominant measures of microbial diversity, or the number of 
operational taxinomical units (OTUs) in each sample: 1) alpha diversity and 2) beta 
diversity. Alpha diversity is defined as the species richness (number) and distribution 
(evenness) of taxa in a single population. Alpha diversity is visualized using rarefaction 
curves in which increasing numbers of sequenced taxa demonstrate increased precise 
estimates of the total bacterial population in the samples. Beta diversity is defined as the 
number of shared taxa between populations. 
1.4 Crohn’s disease   
1.4.1 Crohn’s disease overview  
Next generation sequencing has been used to study microbial profiles in Crohn’s 
disease (CD) animal models and in CD patients. Crohn’s disease, classified as an 
inflammatory bowel disease (IBD), is characterized by inflammation and ulceration 
anywhere along the gastrointestinal tract. Crohn’s disease is distinguishable from 
ulcerative colitis, the other major form of IBD which affects the large intestine only. 
Crohn’s disease was discovered in 1932 by an American gastroenterologist, Dr. Burrill 
Bernard Crohn. In his publication titled “Terminal Ileitis: A new clinical entity,” he 
describes the symptoms that are commonly experienced  [162]. These symptoms 
described include diarrhea, abdominal pain, rectal bleeding, growth stunting (in 
children), fatigue, and weight loss.  
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Formation of fistulae can develop at any time throughout the course of the 
disease and in women, colonic-vaginal fistulae or colonic-anal fistulae can develop and 
cause infections in the lower intestine, vagina or urinary tract. Other patients who do not 
develop fistulae,  may develop intestinal scar tissue that causes blockages [163]. Many 
patients that develop Crohn’s will require surgery to remove the diseased section(s) of 
the GI tract. The disease affects both men and women equally, unlike many autoimmune 
diseases which disproportionately affect women  [164]. While the exact etiology of 
Crohn’s disease is unknown, several factors have been identified that are thought to be 
primary contributors of the disease.  
1.4.2 Causes of Crohn’s disease 
Currently, there are three theories regarding the etiology of CD: 1) the genetic 
autoimmune theory, 2) the mycobacterium infection theory, and 3) the 
immunodeficiency theory [165].  The first theory (genetic autoimmune) suggests that 
there is a genetic predisposition to dysregulation of gastrointestinal immunity and that 
inflammation from CD is an inappropriate immune response to endogenous luminal 
antigens in a genetically susceptible host [166]. Nucleotide-binding oligomerization 
domain 2 (NOD2) is a pattern recognition receptor and is only expressed in specific cells 
in the body including Paneth cells and intestinal epithelial cells. This intracellular sensor 
for small peptides is derived from peptidoglycan, a component of bacterial cell walls. 
The current thought in Crohn’s research is that NOD2 is responsible for several innate 
immune responses such as type I interferon and autophagy [167]. Additionally, toll-like 
receptors are known to participate in cross-talk with NOD2. NOD2 is specifically 
39 
 
responsible for activation of NF-kB, an inflammatory mediator that controls the 
transcription of DNA in the nucleus of the cell. NF-kB is an important component of the 
immune response and can promote other pro-inflammatory chemokines and cytokines 
that are downstream, such as TNFα and IL-1β [168]. This can ultimately cause a 
“cytokine storm,” causing excess inflammation along the GI tract. In addition to NOD2, 
other genetic factors such as CARD15 that exhibit polymorphisms in their LRR (leucine 
rich repeats) as well as polymorphisms in pattern ligand recognition domain of NOD2 
also contribute to the etiology of Crohn’s  [169, 170].   Mutations in NOD2, an abnormal 
balance of intestinal flora, environmental factors such as smoking and stress, and a 
deficiency in IL-10 or other anti-inflammatory cytokines all contribute to Crohn’s 
disease [171].  
Mycobacterium avium subspecies paratuberculosis (MAP) is one of the first 
successful human pathogens and infects at least 2 billion people worldwide [172]. MAP 
can shield itself from a host of immune responses, because of its tough outer cell wall 
and also its ability to prevent phagosome-macrophage fusion. PCR, serum antibodies, 
cultures from intestinal tissue, breast milk, and blood cultures all indicate that CD 
patients have a higher risk for contracting M. tuberculosis than controls without 
CD [173]. For example, one study indicated that 50% of Crohn’s patients (14/28) tested 
positive for M. Tuberculosis antibody vs. 0% of controls [174]. The theory that MAP 
causes CD is one reason why antibiotics are often indicated for clinical treatment, 
because antibiotics are used to treat bacterial infections. Additionally, it is well 
documented that mycobacterial infections are difficult to treat in immunosuppressed 
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patients  [175]. The mycobacterial theory is therefore tied to the “immune deficiency” 
theory suggesting that patients with immune suppression are more susceptibility to 
mycobacterial-related CD.    
The third well-known theory suggests that CD is caused by an immune 
deficiency. Defects in the innate immune system can be responsible for excessive 
inflammatory response. This theory suggests that because of these disturbances with the 
innate immune system, treatment should be focused on augmenting innate immunity, 
rather than suppressing it  [176]. This theory also explains how a pathogen (such as M. 
tuberculosis) might be more likely to invade an already immunosuppressed host. The 
dysfunction of neutrophils might play a role in the pathogenesis of CD.  Post-mortem 
examinations of Crohn’s patients may reveal granulomata, which are present in a 
number of other diseases with known etiologies such as tuberculosis and berylliosis. In 
these diseases, it is the failure of the immune system, more specifically, a defect in 
antigenic clearance from the bowel walls, that causes the granulomata  [177].  
1.4.3 Environmental factors in Crohn’s 
Smoking, stress, oral contraceptive use, antibiotic exposure, and diet are all 
factors that can influence the development, progression, and relapse of CD. Dietary 
factors can also contribute to CD progression [178, 179].   
There are approximately 800-1000 species of bacteria in the human colon  [180]. 
Dethlefsen et al. (2008) indicated that antibiotic usage had a greater longer-lasting 
impact on intestinal commensal flora than originally perceived  [181].  A different study 
followed several subjects who were administered a 7-day treatment with 
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clindamycin [182]. Following this treatment, fecal microbiota samples were collected at 
nine different time points over the course of two years. Compared to the control group, a 
substantial disturbance in the fecal bacterial community was detected, especially in 
Bacteroides isolates. Additionally, Bacteroides levels never returned to normal during 
the 2-yr. time frame. While it has not been determined if prior antibiotic use is causal for 
the establishment of CD, intestinal flora dysbiosis has been a key finding in CD 
patients  [183]. In another study, the influence of smoking and oral contraceptives on 
relapse of CD patients was examined. While women using oral contraceptives and 
smokers had an increased risk of CD relapse, ex-smokers did not [178]. Epidemiological 
evidence has suggested that excess stress can contribute to the course of both ulcerative 
colitis and CD  [184].  Identification of CD risk factors is one step towards management 
and future prevention of flare-ups.  
1.4.4 Incidence of Crohn’s disease 
People of European Jewish descent are four to five times more likely to develop 
CD than others  [185]. Crohn’s disease commonly begins between the ages of 15 and 35, 
and is characterized by recurring “flares” throughout a patient’s life.  Individuals with a 
family member who has CD are 10-30 times more likely to develop CD in his or her 
lifetime when compared to those who do not [186]. Prevalence of CD in North America 
can range from 26 to 198 cases per 100,000, which totals 400,000 to 600,000 
patients [187]. Prevalence in African Americans has increased in recent years, compared 
to Caucasians.  Additionally, rates are substantially lower among Hispanic and Asian 
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populations  [188]. Between 30-60% of patients with CD that are in remission will 
relapse within one year  [189].  
Additionally, geographic variations that correlate with CD incidence are 
documented, especially at northern latitudes. For example, CD has more of a prevalence 
in the northern United States than the southern United States and the Canadian province 
of Manitoba has the highest incidence of CD in the world  [190]. In fact, some studies 
have suggested that exposure to enteric organisms during childhood can program the 
gastrointestinal immune system and prevent IBD later in life  [191, 192, 193].  
1.4.5 Cytokines involved in Crohn’s disease 
Crohn’s disease inflammation is mainly driven by a Th1/Th17 (T helper) 
response that causes an upregulation of proinflammatory cytokines. Proinflammatory 
cytokines are secreted by T-cells and other immune cells such as macrophages that cause 
an inflammatory cascade. Multiple cytokines are also involved in the development and 
progression of CD, however tumor necrosis factor α (TNFα) is the major inflammatory 
player in CD  [194]. Tumor necrosis factor α is involved in multiple inflammatory 
diseases including CD, ulcerative colitis, psoriasis, and Wegener’s granulomatosis. This 
cytokine is responsible for regulating the innate immune response and is produced by 
several immune cells including monocytes, dendritic cells, B cells, CD4+ cells, 
neutrophils, mast cells, eosinophils, fibroblasts, epithelial cells, and smooth muscle 
cells  [195]. Tumor necrosis factor alpha can be produced in membrane-bound or 
secreted forms that are 26 and 17 kD, respectively. When TNFα binds to the TNFα 
receptor, this receptor-ligand interaction causes an intracellular cascade of signaling that 
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leads to phosphorylation of IκBα.  Subsequently, transcription factor NF-κB is activated, 
which increases the production of other proinflammatory cytokines, such as IL-1β, IL-6, 
IL-8 and TNFα [196].  
Tumor necrosis factor α is a key mediator in mucosal inflammation. Dionne et al. 
(1997) determined that TNFα protein and mRNA levels are upregulated  in CD patient 
biopsies, which have also been found to correlate with serum and stool levels  [197]. 
High levels of TNFα have been implicated in growth stunting of children with chronic 
IBD. In a study with 31 children, the growth velocity was significantly lower in children 
with high TNFα levels as a consequence of an IBD  [198].  
Interleukin 1β is another key inflammatory mediator in CD. Polymorphisms in 
IL-1β can also contribute to the course of IBD.  Patients with polymorphisms in allele 1, 
position +3953 and allele 2 at position -511 are more likely to suffer from CD  [199]. If 
both allelic pairs are present, then the patient is more likely to need surgical intervention. 
One study demonstrated that in patients with high concentrations of TNFα, the median 
CD relapse time was 79 days  [200]. When lower concentrations of TNFα were present, 
the median relapse time was 200 days. Interleukin 1β secretion followed a similar trend 
and association with risk of relapse. Low concentrations of IL-1β (<75pg/mL) resulted 
in remission of an average of 180 days, while a high concentration of IL-1β had a relapse 
rate within 1 year. Stable remission was also dictated by the concentration of IL-1β.  
1.4.6 Animal models in IBD 
In order to study IBD and its potential treatments, animal models are needed to 
simulate the disease. There are three predominant rodent models used in IBD research: 
44 
 
1) IL-10 knock-out mice, 2) the Dextran sodium sulfate (DSS) model, and 3) the 2,4,6-
trinitrobenzenesulfonic acid (TNBS) model.  
TNBS colitis produces a Th1-Th17 response with an upregulation of IL-12 and 
IL-17 as the disease becomes increasingly chronic. Because of its characteristic cytokine 
profile, the TNBS colitis model is used as a CD model for acute and chronic 
studies [201]. Once a week, TNBS is administered via intrarectal injection and 
symptoms peak approximately three days afterward. SJL/J mice are the most susceptible 
to TNBS induction because they have a genetically determined high IL-12 response. 
However, the literature suggests that BALB/c strains are less susceptible to TNBS than 
SJL/J mice, resulting in several researchers using BALB/c mice over SJL/J mice to 
reduce mortality rates [202]. Males develop significantly more chronic disease than 
females in the TNBS model. Additionally, the optimal age range of mice induction is 
between 4 to 8 wks. Mice under 4 wks suffer high mortality and mice older than 8 wks 
demonstrate diminished sensitivity [201].  Mechanistically, ethanol (the delivery 
vehicle) breaks the mucosal barrier and TNBS haptenizes the colonic proteins, which 
causes an inflammatory cascade. CD4 T cells are responsible for the cell-dependent 
mucosal immune response in chronic TNBS colitis studies  [203].  
1.4.7 Microbial ecology in Crohn’s disease  
Studies in murine models have also suggested that “spontaneous” colitis can 
develop simply due to the presence of particular strains of bacteria in the lumen  [204]. 
Evidence suggests that the interaction between commensal flora and the immune 
defensive response can initiate or contribute to the pathogenesis of IBD  [193]. Not 
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surprisingly, fecal microbiota can differ substantially between CD patients with the 
active disease and CD patients in remission. For example, proportions of Enterobacteria 
are significantly increased  [205] and lower diversity of Firmicutes exists in patients 
with active CD  [206]. However, because knowledge of microbial interactions is limited, 
an understanding of microbial impact in the context of IBD is also limited. However, a 
diagnosis or prediction of CD cannot be made with microbial profiling results alone.  
 Results from a previous study indicated that twins have highly similar intestinal 
bacteria composition [207]. This study examined twins with CD and also compared them 
with sets of healthy control twins. T Terminal-restriction fragment length polymorphism 
(T-RFLP) and percent guanine to cytosine (% G to C) profiling of the total intestinal 
microbiome was used to assess the differences. In this study, patients with illeal CD had 
an overabundance of E. coli and decreased abundance of Faecalibacterium prausnitzii, 
compared to healthy controls and patients with CD presenting in the colon only.  
 The epithelium of the intestinal mucosa is constantly communicating with 
luminal flora, in addition to a host of adaptive immune cells [208]. It has been suggested 
that commensal bacteria can lessen intestinal inflammation by inhibition of IKBα 
degradation, protein ubiquination and PPARγ-mediated nuclear export of RelA, a 
molecule that is responsible for signal transduction [209]. Goblet cells are highly 
responsible for epithelial and mucosal repair. Goblet cell specific protein RELMβ is 
induced on bacterial colonization [210]. The mucosal immune system can detect 
bacterial antigens on the surface and instigate the appropriate response, depending on 
symbiotic and pathogenic bacteria [211]. M cells and IgA complexes are responsible for 
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monitoring luminal microbes and antigens that are detected by antigen-presenting cells 
(APCs) [212]. Myeloid-derived dendritic cells can then sample bacteria or bacterial 
antigens by the CX3CR1 mechanism [213]. After contact with microbial antigens, 
dendritic cells can produce IL-23, which causes intestinal inflammation in murine 
colitis  [145]. Specific classes of receptors recognize microbial patterns and engagement 
of toll-like receptors by microbes can trigger activation of signal transduction. The 
leucine-rich repeat domain of NOD2 recognizes muramyl dipeptide (MDP), a 
component of bacterial peptidoglycans and can activate NF-kB through the receptor 
serine-threonine kinase-2 [214]. Production of defensins, which are cationic proteins 
protect the body against bacteria and fungi, are also diminished in NOD2 dependent 
CD  [215]. NOD2 can improve antibacterial immunity and bacterial survival due to lack 
of defensins and other factors might enhance bacterial survival  [216].  The 
aforementioned study found that knock-out mice (NOD2-/-) don’t normally develop 
spontaneous intestinal inflammation, unless introduced to a pathogenic bacteria such as 
Listeria.   
1.4.8 Current treatments for Crohn’s disease 
The effectiveness of CD treatments varies substantially from patient to patient. 
There are four predominant classes of drugs currently prescribed for CD: 1) TNFα 
antagonists such as infliximab (Remicade) and adalimumab (Humira), 2) corticosteroids 
such as prednisolone and budesonide, and 3) antibiotics including metronidazole and 
ciprofloxacin and 4) immunosuppresants such as cyclosporine, azathioprine and 6MP. 
Infliximab and similar monoclonal TNFα antibodies, such as adalimumab, have been the 
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most widely recommended in recent years for refractory CD  [217]. In one study, anti-
TNFα (Infliximab) was administered to patients for 6 months [218]. At the end of the 
treatment, red blood cell folate, plasma homocysteine, vitamin B12, methylmalonic acid, 
vitamin D, β-carotene, serum iron, and total iron binding capacity were tested. 
Additionally, the prognostic inflammatory and nutritional index (PINI), an index of 
overall nutrition status and inflammation was assessed through serum measurement of 
alpha1-acid glycoprotein, C-reactive protein, albumin and prealbumin. Infliximab helped 
maintain consistent levels of serum vitamins and improved PINI. One study that 
analyzed 11 clinical trials determined that between 6 and 24% and 21 and 24%  of 
patients on adalimumab and infliximab treatment, respectively, achieved remission when 
compared to the placebo [219].  In the same study, fistulating CD outcomes were 
analyzed and the patient remission rate with TNFα antibodies was between 23 to over 
50% when compared to a placebo.   
Maintenance of CD is a challenge, and can be very costly for the patient.  In 
2011, one study determined that the median cost of infliximab was $10,275.33 and the 
median cost of adalimumab was $9328.75 per patient, with no significant cost difference 
between the two treatments  [220]. Infliximab is prepared and administered to the patient 
as an intravenous injection, as is adalimumab.  Most patients undergo a series of 
injections over the course of several weeks under the supervision of a physician. Side 
effects of infliximab, adalimumab and other anti-TNFα monoclonal antibodies include 
respiratory and urinary tract infections, nausea and vomiting, headache, weakness, fever, 
abdominal pain, rash, flu-like symptoms and high blood pressure.  There is an increased 
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risk of tuberculosis infection as well as an increased risk of certain types of cancers such 
as T-cell lymphoma and skin cancer.  Other side effects include an increased risk of 
hepatitis B infection, allergic reaction and heart failure [217]. Patients receiving TNFα 
antagonists should not receive vaccines during therapy because of the potential for an 
adverse immune response  [221]. 
Corticosteroids are a main staple of Crohn’s treatment and are usually prescribed 
first to reduce inflammation before TNFα antagonists are administered. Corticosteroids 
such as prednisolone and budesonide are administered either intravenously or in tablet 
form. Side effects from corticosteroids are different from TNFα antagonists and include 
facial swelling, excessive hair growth, hyperactivity, high blood pressure, diabetes, 
glaucoma, cataracts due to increased eye pressure and osteoporosis [222].  A new 
corticosteroid, budesonide has been shown to produce fewer adverse steroid 
reactions [223]. Dosage and administration of steroids are closely monitored in children 
because steroids can cause growth stunting  [224]. One of the major problems with 
corticosteroid therapy is the eventual loss of efficacy with successive treatments, which 
typically leads to a change in therapy to antibiotics and/or anti-TNFα antibodies [225].  
Antibiotics are a third class of drugs that are used in treating CD. Several reviews 
have compared antibiotics for short-term and long-term use in CD. For patients with 
active CD, long-term use of either nitroimidazoles or clofazimine is effective  [226]. 
Another study indicated that rifaximin was the most efficacious in inducing 
remission  [227]. Disadvantages of antibiotics include long-standing alterations in 
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intestinal flora, an increase in antibiotic resistant pathogens, and digestive 
discomfort  [228].  
Cyclosporine, an immunosuppressant, is occasionally administered for CD, but 
has yielded mixed results in clinical trials [229]. It is traditionally used in organ-
transplant patients to prevent rejection. Cyclosporine inhibits IL-2, which is responsible 
for T-cell proliferation [230]. IL-2 inhibition has been somewhat successful in CD 
therapy and is typically used when other treatments, such as steroids and antibiotics fail. 
However, cyclosporine has been more successful in achieving remission of ulcerative 
colitis due to the fact that upregulation of IL-2 is more prominent in ulcerative colitis 
than in CD [231]. Other immunosuppressive agents including 6-mercaptopurine (6MP) 
and azathioprine have been used to induce remission of CD [232]. These two drugs are 
cytotoxic to lymphoid cells which makes them an effective treatment in CD  [233].  
1.4.9 Alternative/homeopathic treatments 
Alternative and homeopathic treatments are also used usually as adjunct 
therapies. Probiotics have been under investigation for several years as a potential 
treatment for CD and other diseases and disorders of the bowel. The results from clinical 
trials have been somewhat mixed as to whether or not probiotics are an effective 
treatment for CD [234]. Probiotics are defined as living microorganisms that are 
believed to benefit gastrointestinal health by growing in the intestine and altering the 
composition of existing bacterial colonies. Several strains such as Lactobacilli and 
Bifidobacteria are currently used to treat IBDs [235]. These “good bacteria” allegedly 
alter the flora and the metabolites produced, ultimately resulting in anti-inflammatory 
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effects. However, probiotics have disadvantages in certain patients. For example, 
administration of Lactobacillus GG as a therapeutic treatment for antibiotic-induced 
diarrhea in two pediatric patients resulted in Lactobacillus sepsis (systemic inflammation 
caused by infection)  [236]. Another study found that probiotics were ineffective in 
preventing CD after surgery  [237].  
Vitamin supplementation is a common additional treatment for CD, because the 
activity of CD directly correlates to the malnutrition severity. Because of the loss of 
bone density, it is important to supplement CD patients with vitamin D. One study in the 
American Journal of Gastroenterology showed that antioxidant vitamin supplementation 
in Crohn’s disease reduced oxidative stress [238]. In this study, 70 patients followed at 
several gastroenterology clinics were administered a combination of vitamin C (1000 
mg) and E (800 IU) or a placebo. Plasma vitamin C, tocopherols, alpha and beta 
carotene, lycopene, retinol, B-cryptoxanthin and lutein+ zexanthin was measured. 
Vitamin C and alpha-tocopherol, the type of vitamin E that is absorbed in humans, 
increased significantly after 4 wks. These vitamins were found to decrease lipid 
peroxidation and oxidative stress. Vitamin C can regenerate vitamin E during the 
antioxidant defense mechanism.  
One final alternative therapy for CD involves fecal transplantation. In one case 
study, severe enterocolonic CD was treated with Mycophenolate Mofetil capsules (1.25 
g) daily for 3 wks. There was a marked improvement in CD related symptoms as well as 
a reduction in an intraperitoneal inflammatory mass [239]. Fecal transplants are 
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commonly used to treat C. difficile infection, but less is known regarding their efficacy 
to treat IBDs  [240]. 
1.5 Objectives 
1) To assess the ability of NS to prevent aflatoxicosis in farm-raised tilapia over the 
course of 10 wk.  
2) To evaluate toxicity in red drum exposed to 0-5 ppm AFB1 and determine efficacy of 
NS in preventing aflatoxicosis in fish exposed to 5 ppm AFB1 for 7 wk.   
3) To determine the proper dosage of NS supplementation that mitigates TNBS-induced 
colitis in 5-wk-old BALB/c mice (one-week pilot study). 
4) To quantify cytokine sorption onto NS and assess the ability of NS to reduce CD 
effects and protect the gastrointestinal microbiome in TNBS-induced mice (4- wk 
study). 
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2. THE EFFECT OF NOVASIL DIETARY SUPPLEMENTATION ON THE 
GROWTH AND HEALTH PERFORMANCE OF NILE TILAPIA 
(OREOCHROMIS NILOTICUS) FED AFLATOXIN-B1 CONTAMINATED 
FEED* 
2.1 Introduction 
The aquaculture industry is one of the fastest-growing food sectors in the 
world  [241, 242].  One of the major challenges facing the aquaculture industry is 
eliminating food-borne toxin exposure, such as aflatoxin B1 (AFB1).  Once called “a 
plague of mankind”  [243], aflatoxins are potent, natural toxins produced by Aspergillus 
flavus and A. parasiticus  [244].  These fungi  can contaminate animal feeds when they 
are stored improperly at high temperatures and humid conditions  [245].  Due to climate 
change, aflatoxins are becoming more prevalent and persistent as temperatures and 
droughts increase and previously unaffected regions are compromised  [246].  Of the 
aflatoxin congeners, AFB1 is the most prevalent and toxic  [247].  Chronic exposure to 
AFB1 causes weight loss, immunosuppression, mutagenesis, reproductive alterations and 
carcinogenesis in many species including fish  [248, 249, 250, 251].  Several studies 
have noted an in vitro binding interaction between AFB1 and bacteria including 
Lactobacillus and Bifidobacterium strains  [252, 253, 254]. Aflatoxin B1 has also been 
reported to negatively impact bacteria and microbes in culture by inducing mutations in 
some bacterial species and promoting alterations in microbiota metabolism  [255, 256].   
*The chapter reported has been reprinted with permission from “The effect of NovaSil dietary supplementation on the 
growth and health performance of Nile tilapia Oreobhromis niloticus fed aflatoxin-B1 contraminated feed” by 
Zychowski KE et al. 2013. Aquaculture 376 (2013): 117-123, Copyright 2012 by Elsevier. 
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Alterations in gut bacterial flora can have significant effects on inflammatory conditions, 
disease-resistance and the immune system  [257, 258].  Therefore, there is potential for 
AFB1 to cause alterations in the gut microflora, leading to poor health and growth 
performance in cultured Nile tilapia.   
Due to the high cost of fishmeal and environmental conservation concerns, the 
aquaculture industry is continually seeking plant-based alternatives as feed ingredients to 
replace or supplement it in the diet  [259].  However, feeds with high concentrations of 
plant material, such as peanut, corn, soybean and rice components are more susceptible 
to mycotoxin contamination.  Studies have shown that AFB1 residues in cultured channel 
catfish (Ictalurus punctatus) fillets can be as high as 400 ppb  [260], which is well above 
the current United States Food and Drug Administration (FDA) action level of 20 
ppb  [261].  Researchers have found correlations between AFB1 levels in the diet and 
tissue.  For example,  5 ppb levels were detected in marine sea bass (Dicentratchus 
labrax L.) muscle tissue after a 42-day administration of 180 ppb of AFB1  [262].  
Additionally, it has been determined that AFB1 tissue levels correlate with increasing 
concentrations of AFB1 in the consumed feed  [263]. 
Enterosorption therapy (i.e., calcium montmorillonite clay, NovaSil, NS), is one 
strategy used to decrease the bioavailability and toxicity of ingested AFB1, and has 
resulted in successful reduction of AFB1 exposure biomarkers in the blood and urine 
from many species.  Dietary supplementation with NS is inexpensive and biochemical 
serum analyses have suggested the overall safety of NS in several species  [264, 265, 
266].  NS has a dioctahedral structure and negatively-charged interlayer, which enables 
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AFB1 to tightly adsorb onto the interlamellar surface of the clay  [267]. The objective of 
this study was to evaluate the efficacy of NS enterosorption therapy in reducing the toxic 
effects of AFB1 in Nile tilapia, Oreochromis niloticus.  
2.2 Materials and methods 
2.2.1 Experimental diets 
A basal diet (control) was formulated to contain 320 g of protein kg-1, 35 g of 
lipid kg-1, and an estimated 15.48 kjoules of digestible energy kg-1.  This diet satisfied or 
exceeded the known nutrient requirements of Nile tilapia  [268, 269].  The basal diet was 
spiked with three different levels of AFB1 (0, 1.5, and 3.0 ppm of the dry weight) and 
three different NS concentrations (0, 0.5 and 1.0% of the dry weight) in a factorial 
arrangement (Table 4).  Prior to its addition, AFB1 (Sigma-Aldrich, Saint Louis, MO) 
was dissolved in chloroform and further added to Celufil, a non-nutritive bulking agent 
(USB Corporation, Cleveland, OH).  The chloroform was then evaporated in the dark 
under a fume hood.  All dry ingredients with the exception of the AFB1 were mixed in a 
V-mixer for 20 minutes and then mixed with oil and 1L of water in a Hobart mixer 
(Hobart Service, Troy, OH) for 1 hr.  Aflatoxin B1-spiked Celufil was then thoroughly 
mixed into the respective diets to provide a concentration of 1.5, or 3.0 ppm, 
immediately before the addition of soybean oil and water.  Aflatoxin1-free Celufil was 
also included in the diets without AFB1 for comparison.  All feeds were cold-pelleted 
through a 3-mm die on a meat grinder attachment, and air-dried in the dark for 24 hr.  
The diets were then bagged and stored at -20°C until further use.  The nine experimental 
diets contained the following: (1) 0 ppm AFB1+ 0% NS, (2) 1.5 ppm AFB1 + 0% NS, (3)
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Table 4. Diet formulation and proximate composition of experimental treatments (g/ 100g of dry weight) 
          Level of AFB1 (ppm) 0.0 1.5 3.0 0.0 1.5 3.0 0.0 1.5 3.0 
Level of NS (%) 0.0 0.0 0.0 0.5 0.5 0.5 1.0 1.0 1.0 
Menhaden Meal1 11.0 11.0 11.0 11.0 11.0 11.0 11.0 11.0 11.0 
Soybean Meal2 49.3 49.3 49.3 49.3 49.3 49.3 49.3 49.3 49.3 
Dextrinized Starch3 20.3 20.3 20.3 20.3 20.3 20.3 20.3 20.3 20.3 
Vitamin Premix4 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 
Mineral Premix3 4.0 4.0 4.0 4.0 4.0 4.0 4.0 4.0 4.0 
Carboxymethyl Cellulose3 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 
Soy oil5 4.8 4.8 4.8 4.8 4.8 4.8 4.8 4.8 4.8 
CaPO4, dibasic3 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 
Glycine6 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 
DL-Methionine3 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.15 
NS7 0.0 0.0 0.0 0.5 0.5 0.5 1.0 1.0 1.0 
AFB1(g)
8 0.0 150.0 300.0 0.0 150.0 300.0 0.0 150.0 300.0 
Celufil6 3.5 3.5 3.5 3.0 3.0 3.0 2.5 2.5 2.5 
Proximate Composition (g  kg
-1
)          
         
Protein 34.4 33.8 33.6 33.8 34.7 33.6 33.0 33.8 36.4 
Lipid 7.5 6.9 6.1 8.0 6.0 8.2 6.3 8.2 9.7 
Dry Matter  90.8 90.9 91.3 91.3 90.6 91.3 90.6 90.4 90.3 
Ash 8.9 8.9 8.9 9.4 9.4 9.3 9.7 9.8 9.8 
          
 
1Omega Protein, Houston, TX, 2Producers Cooperative Association, Bryan, TX, 3MP Biomedicals LLC, Solon, OH, 4Contains (as g kg-1): 
Ca(C6H10O6)·5H2O, 348.49; Ca(H2PO4)2·H2O, 136.0; FeSO4·7H2O, 5.0; MgSO4·7H2O, 132.0; K2HPO4, 240.0; NaH2PO4·H2O, 88.0; NaCl, 
45.0;AlCl3·6H2O, 0.15; KI, 0.15; CuSO4·5H2O, 0.5; MnSO4·H2O, 0.7; CoCl2·6H2O, 1.0;ZnSO4·7H2O, 3.0; Na2SeO3, 0.011., 
5Crisco, Orrville, OH, 
6USB Corporation, Cleveland, OH, 7Engelhard Corporation, Jackson, MS , 8Sigma-Aldrich, St. Louis, MO 
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3.0 ppm AFB1 + 0% NS, (4) 0 ppm AFB1 + 0.5% NS, (5) 1.5 ppm AFB1 + 0.5% NS, (6) 
3.0 ppm AFB1 + 1.0% NS, (7) 0 ppm AFB1 + 1.0% NS, (8) 1.5 ppm AFB1 + 1.0% NS, 
and (9) 3.0 ppm AFB1 + 1.0% NS.    
 2.2.2 Fish stock and culture conditions 
Juvenile tilapia were shipped to the Texas A&M Aquacultural Research and 
Teaching facility from a commercial producer.  Fish were conditioned in round tanks 
and then in the aquaria with a commercial diet (Rangen, Inc. Angelton, TX) for a period 
of 2 wk, followed by 1 wk on the control diet (0 ppm AFB1 + 0% NS) prior to the start 
of the trial.  The feeding trial was conducted in a closed, recirculating 110-L aquaria 
system, where salinity and temperature were maintained at 5 ppt and 37°C. Water flow 
was set at a rate of 1 L min-1 and aeration provided a dissolved oxygen level of at least 
80% air saturation.  The fish were exposed to a diurnal light:dark cycle of 12:12 hr with 
fluorescent lighting controlled by timers.  Ammonia, nitrate, and nitrite were kept below 
toxic levels by the use of biofiltration.  The nine treatments were randomly assigned to 
triplicate aquaria.  Fifteen fish of similar size (average initial weight 2 ± 0.1 g/fish) were 
stocked into each of 27 aquaria.  The fish were fed twice daily their assigned diet at 8 am 
and 4 pm over the course of 10 wk.  Each diet was fed to the fish at a rate of 7% of 
initial body weight and adjusted over the course of the trial to 3% in order to minimize 
overfeeding and maintain a feeding rate close to satiation.  Fish in each tank were group-
weighed weekly to adjust feeding rates.  Mortalities and abnormalities were monitored 
and recorded on a daily basis.  
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2.2.3 Fish responses  
At the end of the trial, weight gain (% of initial weight), feed efficiency (g weight 
gain/g dry diet fed), and survival (100 x (final # of fish)/ initial # of fish) measurements 
were calculated.  Additionally, three fish were sampled from each of the 27 aquaria at 
the end of the feeding trial and each separately homogenized in a blender.  Moisture, 
ash, protein and lipid analysis of whole-body samples were completed according to 
established procedures  [270].  Organ to whole-body weight somatic indices were 
calculated for heart, spleen, liver (HSI), intraperitoneal fat (IPF), and fillet and averaged 
based on two fish per tank (six per treatment) using the formula: Somatic Index = (organ 
weight/body weight)*100.  Fish were hand filleted by one individual to maintain 
consistency.  The fillets were skinned and any remaining pin bones were manually 
removed.  The dextral side of each fish was filleted and weighed.  The fillet weight was 
then doubled for each fish and the somatic index was calculated.    
2.2.4 Immunological measurements 
Extracellular superoxide anion production was measured in head-kidney 
macrophages using the method described in Secombes et al.  [271] and modified by 
Sealy et al.  [272] using three fish per aquaria (9 per treatment).  Oxidative radical 
production in whole blood neutrophils was determined using a nitro blue tetrazolium 
(NBT) assay  [273, 274].  Two fish from each tank (6 fish per treatment) were 
euthanized and 1 mL of blood was drawn from each fish using 1 mL pre-treated 
heparinized syringes. Additionally, plasma lysozyme concentration was analyzed from 
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two fish per tank (6 per treatment) using a turbidimetric method as previously 
published  [274, 275].  
2.2.5 Characterization of gut microbiota 
Digesta was collected under sterile conditions from the intestines of three fish per 
aquaria.  DNA isolation (QIAamp DNA Mini Kit (Qiagen, Valencia, CA)), PCR and 
denaturing gradient gel electrophoresis (DGGE) were performed according to a modified 
method described in Hume et al.  [276]. Visualization of bands was accomplished using 
an imager (Alpha Innotech, San Leandro, CA).  Band pattern relatedness (percentage 
similarity coefficient) and dendrogram construction were determined according to the 
methods of Hume et al. (2003).   
2.2.6 Histology  
Upon termination of the trial, livers from six fish per treatment (two per tank) 
were dissected and stored in Davidson’s solution.  Within 24 hr, the livers were rinsed 
with 70% ethanol and transferred to vials containing 10 mL fresh 70% ethanol, until 
further histological processing.  All samples were transported to the Texas A&M 
Veterinary Integrative Biosciences Histology Laboratory for further processing.  
Samples were embedded in paraffin and sectioned at 5 µm.  The samples were further 
mounted on glass slides and stained with hematoxylin and eosin.  Slides were blind-
examined under a light microscope for histopathological changes.  Lesions were 
examined including cellular pleomorphism, nuclear pleomorphism, dysplasia, hydropic 
degeneration, fatty degeneration, necrosis, leukocyte infiltration and inclusion bodies  
and were graded on a scale of 0 to 4 for each slide, 0 = no pathological changed 
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apparent, 1 = mild, 2 = moderate, 3 = moderate to severe, and 4 = severe lesions.  All 
lesions from each slide were then averaged for an overall liver histopathological score 
per fish.   
2.2.7 HPLC analysis of AFB1 in fish feed 
In order to confirm targeted levels and demonstrate the binding capacity of NS, 
AFB1 was extracted from each diet with slight modifications from previously established 
methodology  [277, 278].  Briefly, three samples totaling 50 g of diet were pooled 
according to treatment.  A 250 mL solution of 70/30% (v/v) methanol/water was blended 
with the 50 g diet samples.  The sample was then filtered using medium filter paper 
(VWR, Atlanta, GA), and the filtrate was collected into a clean plastic centrifuge tube, 
and capped tightly.  One gram of NaCl and 20 mL HPLC water (VWR) were added to 
each sample, followed by thorough vortexing.  The solution was then filtered through a 
microfiber filter (VWR).  Filtered extract (6 mL) was pipetted into a plastic syringe 
barrel reservoir and pushed through a Vicam Aflatest P column (Vicam, Milford, MA) at 
a rate of 2 drops/sec.  Deionized water (10 mL) was added to the syringe barrel and 
pushed through at a rate of 2 drops/sec.  The column was rinsed once more with 10 mL 
of water.  Aflatoxin B1 was eluted from the column into a glass tube with 1.0 mL of 
methanol.  The solution was filtered through a 0.45-μm syringe filter (VWR).  Using a 
mobile phase of 3:1:1 Water:Acetonitrile:Methanol, the samples were then injected into 
the HPLC equipped with a Waters Spherisorb® 5 µm 4.6x150 mm column and 2475 
Fluorescence Detector (Waters, Milford, MA).  Quantification of AFB1 was achieved 
using the Breeze Software (Waters Milford, MA).  Results from HPLC analyses 
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indicated that endogenous levels of AFB1 were negligible (<2.5 ppb AFB1) in the 0 ppm 
AFB1+0% NS, 0 ppm AFB1+0.5% NS, and 0 ppm AFB1+1.0% NS diets. Of the 
extracted AFB1, NS bound an average of 57.7% of the AFB1 in the targeted 1.5 ppm 
AFB1 dietary treatments and 43% in the targeted 3.0 ppm AFB1 diets.   
2.2.8 Statistical analysis 
The Statistical Analysis System (SAS) version 9.2 (SAS Institute Inc., Cary, NC) 
was used to compute all statistics. All parameters, except for histopathological scores, 
were first subjected to a two-way ANOVA.  Specific differences among treatments and a 
comparison of means were further analyzed using Duncan’s multiple range test.  
Histopathological scores were analyzed using the nonparametric Aligned Rank 
Transform as described in  [279] and then subject to a two-way ANOVA and Duncan’s 
multiple range test.  Treatment effects were considered significant at P ≤ 0.05.   
2.3 Results 
2.3.1 Growth performance  
Survival was not significantly affected by AFB1, NS, or the combination of both 
treatments.  However, AFB1 negatively impacted feed efficiency (P < 0.001) and weight 
gain at 3 ppm (P = 0.018), regardless of NS inclusion in the diet (Table 2).  The inverse 
relationship between increasing AFB1 concentration and decreasing weight gain and 
feed efficiency occurred in a linear manner, with an R2 = 0.94 and 0.95, respectively 
(Fig. 6).   NS-supplemented fish exposed to 3 ppm AFB1exhibited higher feed efficiency 
and weight gain than 3 ppm exposed fish without NS; however, these trends were not 
found to be statistically significant (Table 5). 
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Figure 6. AFB1 effect on feed efficiency and weight gain. Increasing AFB1 levels inversely correlated with decreasing feed 
efficiency (right axis), and weight gain (left axis) in Nile tilapia (Oreochromis niloticus), regardless of % NS inclusion (n=9). 
R2 values for linear trends were 0.9403 and 0.9521 for weight gain and feed efficiency, respectively.  
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Table 5. Growth performance of tilapia fed different concentrations of AFB1 and 
NovaSil 1,2 
 
Variable 
Level of NS 
(%) 
Weight gain 
(%)3 
Survival (%) Feed Efficiency 
Level of AFB1 
(ppm) 
 
        Individual treatment means 
0 0 636 88.8 0.68 
0 0.5 542 97.7 0.64 
0 1 643 93.3 0.67 
1.5 0 550 93.3 0.64 
1.5 0.5 499 97.7 0.63 
1.5 1 627 95.5 0.65 
3 0 375 95.5 0.54 
3 0.5 522 100 0.62 
3 1 451 100 0.59 
Pooled Std. Error 35.895 2.051 0.012 
     
  
              Means of main effect 
0 
 
607a 98.5 0.66a 
1.5 
 
559a 95.5 0.64a 
3 
 
449b 93.3 0.58b 
 
0 520 98.5 0.62 
 
0.5 521 96.2 0.63 
 
1 574 92.5 0.64 
     
                   ANOVA: P-values 
AFB1  
  0.018* 0.227 <0.001* 
NS 
 
0.494 0.147 0.586 
AFB1 x NS 
 
0.311 0.948 0.139 
 
 
 
1Values are means of three replicate groups of fish (n=3).   
2Values in a column that do not have the same superscript are significantly different according to 
Duncan’s multiple range test (P<0.05).   
3Initial average weight was 10.9 ± 0.4 g/fish  
*Indicates significance (P<0.05) 
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Table 6. Immune parameters of tilapia fed different concentrations of AFB1 and 
NovaSil1 
 
Variable 
Level of NS 
(%) 
Plasma Lysozyme 
(units/mL) 
NBT (mg/mL 
blood)2 
Extracellular 
Superoxide Anion 
(mmol)3 
Level of AFB1 
(ppm)  Individual treatment means 
0 0 182 2.46 1.60 
0 0.5 221 2.40 1.24 
0 1 183 2.49 2.25 
1.5 0 112 2.64 0.50 
1.5 0.5 118 2.89 0.64 
1.5 1 220 2.54 0.88 
3 0 152 2.31 0.98 
3 0.5 127 2.42 1.01 
3 1 180 2.57 1.16 
Pooled Std. 
Error  
12 0.057 0.119 
 Means of main effect 
0 
 
196 2.45 1.7a 
1.5 
 
150 2.69 0.67c 
3 
 
153 2.43 1.05b 
 
0 148 2.47 1.03x 
 
0.5 155 2.57 0.96x 
 
1 194 2.53 1.43y 
  ANOVA: P-values 
AFB1  
0.391 0.243 <0.001* 
NS 
 
0.687 0.823 0.006* 
AFB1 x NS  
0.335 .698 .157 
 
 
 
1 Values in a column that do not have the same superscript are significantly different according to 
Duncan’s multiple range test (P<0.05).   
2 Values are means of determinations on two fish from each of three replicate groups (6 fish/treatment, 
n=6).   
3 Values are means of three composite samples of kidney cells from three fish in each of the three replicate 
groups (n=3). 
*Indicates significance (P<0.05) 
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2.3.2 Immune parameters 
Plasma lysozyme concentrations were not significantly altered with either the 
AFB1 or NS treatments (Table 6).  Likewise, there were no significant differences (P > 
0.05) in the neutrophil respiratory burst (mg/NBT) among treatments.  Interestingly, 
extracellular superoxide anion production was significantly increased with 1% NS 
dietary supplementation (P = 0.006), and decreased in the 1.5 and 3.0 ppm AFB1-treated 
fish as compared to controls (P < 0.001).   
2.3.3 Organosomatic indices and proximate composition of whole-body tissues 
There were no statistically significant differences between the somatic indices of 
heart, spleen or IPF between treatment groups (Table 7).  A significantly lower fillet 
weight was recorded in the 0.5% and 1% NS treatment groups compared to the control 
(P = 0.008).  However, this outcome was not observed in the AFB1 treatment groups.  
HSI levels were also significantly decreased in groups exposed to AFB1 at both 1.5 and 
3.0 ppm (P < 0.001).  No significant differences in percent lipid, protein, moisture, or 
ash were documented in treated fish, indicating that neither AFB1, NS, nor a 
combination of the two affected whole-body proximate composition (Table 8). 
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Table 7. Organ ratios of tilapia fed different concentrations of AFB1 and NovaSil
1,2 
 
 
1 Values in a column that do not have the same superscript are significantly different according to 
Duncan’s multiple range test (P<0.05).  2Values are means of determinations on two fish from each of the 
three replicates (6 fish/treatment, n=6).  3Hepatosomatic index4Intraperitoneal fat*Indicates significance 
(P<0.05) 
 
 
 
 
Variable Level of NS (%) Heart Spleen Fillet HSI3 IPF4 
Level of AFB1 (ppm)                          Individual treatment means 
0 0 0.092 0.097 26.60 1.81 0.174 
0 0.5 0.100 0.089 23.80 1.59 0.204 
0 1 0.114 0.162 23.31 1.34 0.158 
1.5 0 0.111 0.118 29.60 0.94 0.232 
1.5 0.5 0.114 0.117 18.64 1.20 0.257 
1.5 1 0.100 0.124 26.58 1.20 0.115 
3 0 0.094 0.14 28.09 1.10 0.230 
3 0.5 0.097 0.095 26.48 0.81 0.066 
3 1 0.088 0.098 24.69 0.95 0.111 
Pooled Std. Error 0.002 0.007 0.513 .042 .0300 
                                 Means of main effect 
0 
 
0.102 0.116 24.57 1.58a 0.261 
1.5 
 
0.109 0.120 24.94 1.12b 0.218 
3 
 
0.093 0.111 26.42 0.959b 0.268 
 
0 0.099 0.118 28.09a 1.28 0.294 
 
0.5 0.104 0.100 22.97b 1.20 0.262 
 
1 0.101 0.128 24.86b 1.16 0.190 
  
                                 ANOVA: P-values 
AFB1  
0.147 0.905 0.421 <0.001* 0.822 
NS 
 
0.819 0.399 0.008* 0.614 0.486 
AFB1 x NS  
0.372 0.293 0.055 0.139 0.687 
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Table 8. Whole-body proximate composition of tilapia fed different concentrations of 
AFB1 and NovaSil (% of wet weight)
1
 
Variable Level of NS Lipids Protein  Moisture Ash 
Level of AFB1 
(ppm) 
 
                          Individual treatment means 
0 0 3.59 15.08 23.78 2.80 
0 0.5 3.38 14.94 24.21 4.04 
0 1 3.79 13.84 21.01 3.31 
1.5 0 3.44 16.76 24.79 3.81 
1.5 0.5 4.15 16.23 24.98 4.21 
1.5 1 3.32 13.96 20.69 2.72 
3 0 2.81 15.99 22.90 3.84 
3 0.5 3.92 15.68 22.98 2.82 
3 1 3.45 15.73 24.12 3.41 
Pooled Std. Error 0.099 0.205 0.242 0.13 
  
Means of main effect 
0 
 
3.59 14.62 23.00 3.38 
1.5 
 
3.64 15.65 23.49 3.58 
3 
 
3.39 15.8 23.34 3.35 
 
0 3.28 15.94 23.82 3.48 
 
0.5 3.82 15.62 24.06 3.69 
 
1 3.52 14.51 21.94 3.15 
  
ANOVA: P-values 
AFB1   
0.829 0.357 0.89 0.902 
NS 
 
0.463 0.251 0.105 0.618 
AFB1 x NS  
0.644 0.777 0.199 0.379 
 
1Values are means of determinations on three fish from each of the three replicates (n=3). 
 
2.3.4 Histology 
Hepatocyte necrosis, cellular pleomorphism, nuclear pleomorphism, dysplasia, 
hydropic degeneration, and fatty degeneration were detected in the liver of fish exposed 
to AFB1.  Similarly, fish fed AFB1 had greater liver pathological damage than those 
without AFB1 , where the major histopathological lesions observed were related to 
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cellular changes (Fig. 7), contributing to a higher histopathological score (Fig. 8).  
Inclusion of NS in the diet did not significantly impact histopathological outcomes.    
 
 
Figure 7. Microphotographs of liver sections Nile tilapia (Oreochromis niloticus) were 
fed combinations of aflatoxin B1 (AFB1) and NovaSil (NS) (400 magnification, H/E 
staining). 0 ppm AFB1 + 0% NS (A) and 0 ppm AFB1 + 0.5%NS (B) treatments resulted 
in normal histological structure, whereas fish fed 1.5 ppm AFB1 + 0.5% NS (C) and 1.5 
ppm AFB1 (D) showed marked cellular pleomorphism, characterized by zones of 
enlarged, stellated or spindle-shaped hepatocytes (*) surrounded by small polyhedric-
shaped hepatocytes (arrow). Increased fatty degeneration was observed in fish fed 1.5 
ppm AFB1 (D). Scale bar = 50µm.  Results were based on two fish from each of the 
three replicate groups (n=6). 
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2.3.5 Bacterial microbiotia and DGGE 
Denaturing gradient gel electrophoresis analysis indicated that none of the 
treatments were significantly different from each other.  Overall, neither AFB1, NS, nor 
a combination of the two significantly altered gut microbiota in tilapia (Fig. 9).   
  
 
Figure 8. Quantification of histopathological effects. Overall histopathological score per 
treatment (NS = NovaSil; AFB1 = aflatoxin B1) in Nile tilapia (Oreochromis niloticus).  
Bars in the figure that do not have the same letter are significantly different according to 
Duncan’s multiple range test (P<0.05).  Aflatoxin B1 had a significant effect on total 
histopathological score (P<0.001). There was no statistical difference between NS levels 
(P=0.1347), or AFB1xNS (P=0.1770).   Results were based on two fish from each of the 
three replicate groups (n=6). 
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Figure 9. Denaturing gradient gel electrophoresis of bacterial 16S rDNA amplicons 
from tilapia intestinal contents. The bar above the figure corresponds to the percentage 
similarity coefficients.  Three fish per tank in three separate aquaria were combined per 
treatment (n=9).   
 
2.4  Discussion 
Overall, AFB1 had a significant impact on tilapia over 10 wk.  With decreased 
weight gain and lower feed efficiency, 3 ppm AFB1-exposed fish performed poorly 
compared to 1.5 ppm AFB1-exposed fish and the controls.  Reduction in weight gain and 
decreases in feed efficiency at the higher dose confirm the anti-nutritional effects of 
AFB1 as seen in similar studies  [280].  However, this work is the first to report that 
detrimental effects can occur in tilapia exposed to relatively low AFB1 concentrations (3 
ppm) in 10 wks, a relatively short time-span when contrasted to a full growth cycle. As 
in other species, the target organ of AFB1 in tilapia is the liver, where it is known to 
induce toxicity.  AFB1 binds to DNA, creating the AFB1-8,9-epoxide which is involved 
in the development of fatty liver, necrosis and carcinogenesis in fish and other 
animals  [281, 282].  In agreement, we found that HSI decreased significantly in groups 
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exposed to AFB1, and damage to the liver was histologically detected at levels as low as 
1.5 ppm of AFB1.  Histopathological changes in the liver and lowered HSI suggest a 
progression towards AFB1-induced heptocarcinogenesis.   
 Immunosuppressive consequences have been demonstrated in a broad range of 
AFB1-exposed animals including turkeys, chickens, trout, humans and others.  
Detrimental effects on the animal’s immunity are likely due to interference with specific 
biochemical and physiological pathways  [283].  Decreased extracellular superoxide 
anion production, an indicator of immunosuppression, has been previously reported in 
murine species as well as fish  [284, 285].  One study found a decrease in total 
superoxide anion production in AFB1-exposed tilapia  [286], but did not report a 
decrease in extracellular superoxide anion production, as specifically described in this 
study.  Because the production of reactive oxygen species such as superoxide anion is 
deployed by the immune system to kill invading microorganisms, AFB1-induced 
reductions in free radical production may result in a decreased resistance to pathogens 
including bacteria (Iwama and Nakanishi, 1996).  However, further studies examining 
the effects of AFB1-exposure in disease-challenged tilapia are needed to determine the 
extent of this correlation.  
Aflatoxin B1 exposure typically occurs via food consumption and could 
potentially alter bacterial microbiota in the gut due to its previously established 
antibacterial activity  [288, 289].  Aflatoxin B1 has also been shown to bind to naturally 
occurring bacteria in the gut essential for digestion  [252, 254, 290].  It is possible that 
alterations in gut bacterial flora, essential for metabolism and digestion, may negatively 
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impact animals  [291].  However, this hypothesis could not be substantiated given the 
obtained DGGE data.  Therefore, the observed changes in biological parameters caused 
by AFB1 could not directly be attributed to alterations in gut bacterial microbiota.   
Overall, NS alone at 0.5 and 1.0% inclusion rates did not impact any of the 
growth parameters and the treatments did not produce results significantly different from 
the controls, with the exception of a decrease in fillet weight.  Interestingly, the 0 ppm 
AFB1 + 1% NS treatment produced a sharp increase in extracellular superoxide anion, as 
compared to the control group (P < 0.05), suggesting that NS alone might have a 
positive influence on the tilapia immune system.  In future studies, serum levels of fish 
supplemented with NS will be monitored and analyzed to detect any changes in mineral 
and vitamin content that may be responsible for enhanced immunity.    
 Although not significant, NS had a positive influence on some of the parameters 
tested. Results were inconclusive regarding its efficacy and varied between 1.5 and 3.0 
ppm AFB1 levels. In published studies using clays to sorb toxins in feeds, the clays were 
either administered in a dry form added to commercial feeds or in an encapsulated 
supplement  [264, 292, 293].  The efficacy of NS has been cited repeatedly in various 
species  [264, 294], but due to the high degree of processing necessary for the production 
of fish feeds, there is potential for NS to interact with various components in the feed 
matrix.  Components in the feed may have been sequestered in the negatively-charged 
interlayer of NS during mixing, thereby rendering it less capable of sorbing 100% of 
AFB1 at the administered levels.  A previous study determined that 0.5% hydrated 
sodium aluminosilicate was not effective in preventing liver lesions in rainbow trout 
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exposed to AFB1 and may have interfered with some essential feed components  [295].  
Somewhat similar to this study, the aluminosilicate was added to the feed before the 
pelletization step and did not prevent the toxic effects of AFB1 from altering the liver.  
Conversely, another study suggested that 2% sodium bentonite decreased liver, kidney 
and feces AFB1 in 20 ppb AFB1-exposed trout.  However, the diets were prepared by 
loading the previously dried feed components into hollow gelatin capsules, followed by 
the addition of 0.1 mL methanol-AFB1 solution to each gram of sample.  The increase in 
the inclusion level of clay, the difference in feed preparation, or the different 
experimental endpoints tested may have been responsible for the significant decrease in 
toxicity  [296].  Yet another study found that 0.5% montmorillonite and bentonite both 
decreased hepatic DNA damage in 1.5 ppm AFB1-exposed tilapia  [297].  Discrepancies 
in the literature indicate that further research concerning AFB1 binders in farm-raised 
fish is needed.  
On the whole, AFB1 had a negative impact on tilapia weight gain and feed 
efficiency over a relatively short span of 10 wk. AFB1 also negatively impacted multiple 
physiological and biological parameters significantly, including HSI and macrophage 
extracellular superoxide anion production with both 1.5 and 3.0 ppm treatment levels.  
Although a degree of protection was afforded in some cases with the inclusion of NS in 
the fish feed, indeed, future studies should strive to achieve mitigation for aflatoxicosis 
in tilapia by determining an effective dosing method for NS in fish.  This method may 
require supplementation separate from the feed itself, allowing for AFB1 sorption 
without food matrix interference.   A binder such as NovaSil, if utilized effectively, 
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could reduce exposure to AFB1, thereby preventing bioavailability and subsequent 
effects, such as immunosuppression, liver damage and decreases in growth parameters.  
Decreasing the incidence of aflatoxicosis in farm-raised fish would ultimately prevent 
economic loss for the industry.    
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3. THE EFFECT OF AFLATOXIN-B1 ON RED DRUM (SCIAENOPS 
OCELLATUS) AND ASSESSMENT OF DIETARY SUPPLEMENTATION OF 
NOVASIL FOR THE PREVENTION OF AFLATOXICOSIS 
3.1 Introduction 
Mycotoxins are toxic metabolites produced by a diverse group of fungi that 
contaminate agricultural crops prior to harvest or during storage post-harvest  [298, 299]. 
Aflatoxin B1 (AFB1), a mycotoxin produced by Aspergillus flavus and A. parasiticus, is 
one of the most potent, naturally-occurring carcinogens known to mankind. Aflatoxin B1 
exposure causes decreases in weight gain, growth stunting and immunosuppression in 
animals, while increasing hepatocellular carcinoma incidence  [300]. Different species 
including humans, poultry, swine, and fish all exhibit varying levels of mortality and 
morbidity upon exposure to AFB1  [249, 301, 302]. However, because the damaging 
AFB1 effects are largely species and dose-specific, additional studies are necessary to 
determine AFB1 susceptibility for at-risk unevaluated species.   
As a vital part of the global food industry, aquaculture contributes nearly half of 
all food of aquatic origin intended for human consumption  [303].  Fishmeal, one the 
most expensive fish feed ingredients, is widely used in the aquaculture industry as the 
major protein source for farm-raised fish  [304]. Menhaden (Brevoortia sp) is a clupeid 
fish species and the most prevalent form of fishmeal used in the North America  [305] .  
*The chapter reported has been reprinted with permission from “The Effect of Aflatoxin-B1 on Red Drum (Sciaenops 
ocellatus) and Assessment of Dietary Supplementation of NovaSil for the Prevention of Aflatoxicosis by Zychowski, 
KE et al. Toxins 5.9 (2013): 1555-1573. The  publisher, MDPI, does not hold the copyright to the published material. 
The authors (Zychowski, KE et al.) are the original copyright holders.  
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Recent studies have been directed toward the development of plant-based 
alternative protein sources such as soybean, peanut, corn and cottonseed meal  [306, 307, 
308, 309]. However, incorporation of plant-based ingredients into feed increases the risk 
of AFB1 contamination and subsequent exposure.  Aflatoxin B1 presence in aquaculture 
feeds and fish feed ingredients has been well-documented, especially in developing 
countries  [310, 311, 312].   
One strategy to reduce aflatoxin exposure in humans and animals is the use of 
enterosorption therapy. NovaSil (NS), a calcium montmorillonite clay, binds AFB1 in 
the gastrointestinal tract, thereby reducing overall AFB1 bioavailability  [313]. With a 
dioctahedral-layered structure and negatively charged interlayer, NS has high affinity 
and capacity for AFB1 molecules, which exhibit a partial positive charge  [314]. 
Numerous in vivo studies have demonstrated the safety and efficacy of this 
technology  [266, 294, 315], although additional studies are needed to determine the 
efficacy and proper dosage for farm-raised fish  [316].   
Red drum, Sciaenops ocellatus, is a common recreational and commercial fish 
native to the Atlantic and Gulf Coast regions of the United States  [317].  Red drum is 
currently farmed in China, Israel, Ecuador and North America  [318]. Despite its 
prevalence and economic importance to the food industry, no studies have evaluated red 
drum AFB1 susceptibility. The study presented here was designed to address two 
objectives: 1) to evaluate red drum susceptibility to AFB1 using a multi-level AFB1 
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challenge incorporated into the feed and 2) to assess the ability of NS to prevent AFB1 
toxicity in red drum.    
3.2. Materials and methods 
3.2.1 Experimental diets 
The control basal diet was composed of 400 g protein kg-1 and 110 g lipid kg-1, 
containing an estimated 3.5 kcal digestible energy kg-1 (Table 9) and fulfilling all 
documented nutrient requirements of red drum  [319]. Aflatoxin B1 (Sigma-Aldrich, 
Saint Louis, MO) was incorporated into the diet by first dissolving the AFB1 in 
chloroform and subsequently adding it to Celufil, a non-nutritive bulking agent (USB 
Corporation, Cleveland, OH). The chloroform was evaporated to dryness from the 
mixture in a dark room under a fume hood, leaving the Celufil amended with AFB1. A 
V-mixer was used to blend all dry ingredients, with the exception of the AFB1-spiked 
Celufil, for 20 min. The dry ingredients were then mixed with the AFB1-spiked Celufil 
in a Hobart mixer until homogeneity was achieved. The oil component and 700 mL of 
H2O were further added to the dry ingredients and mixed for 1 h. Aflatoxin-free Celufil 
was incorporated into the basal diet for comparison. The moist feed was cold-pelleted 
through a 3-mm die on a meat grinder attachment and dried in a dark room for 24 h. 
Diets were subsequently bagged and stored at -20 ˚C until needed. The ten diets 
contained the following: 0 ppm AFB1 (i.e., 0 ppm AFB1+ 0% NS), 0.1 ppm AFB1, 0.25 
ppm AFB1, 0.5 ppm AFB1, 1 ppm AFB1, 2 ppm AFB1, 3 ppm AFB1, 5 ppm AFB1, 5 
ppm AFB1 + 1% NS and 5 ppm AFB1+ 2% NS. A NS control group was not included 
since its safety was previously evaluated in this species (unpublished data).    
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3.2.2 Fish stock and culture conditions 
Fingerling red drum were transported from the Texas Parks and Wildlife 
hatchery located at Lake Jackson, TX to the Texas A&M Aquacultural Research and 
Teaching Facility. Fish were stocked and conditioned in round tanks with a commercial 
diet (Rangen, Inc. Angelton, TX) for 2 weeks, then transferred to aquaria and 
conditioned for 1 week on the basal diet. A closed, re-circulating system was composed  
 
Table 9. Ingredient and proximate composition of experimental diets (g/ 100 g of dry 
weight) 
Level of AFB1 (ppm) 0 0.1 0.25 0.5 1 2 3 5 5 5 
Level of NS (%) 0 0 0 0 0 0 0 0 1 2 
Menhaden Meala 34.9 34.9 34.9 34.9 34.9 34.9 34.9 34.9 34.9 34.9 
Soybean Mealb 27.3 27.3 27.3 27.3 27.3 27.3 27.3 27.3 27.3 27.3 
Dextrinized Starchc 16. 16.5 16.5 16.5 16.5 16.5 16.5 16.5 16.5 16.5 
Menhaden Oila 5.6 5.6 5.6 5.6 5.6 5.6 5.6 5.6 5.6 5.6 
Vitamin Premixe 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3.0 
Mineral Premixc 4.0 4.0 4.0 4.0 4.0 4.0 4.0 4.0 4.0 4.0 
CMCc 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 
Glycinef 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 
Lysinef 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
NSg 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 2.3 
AFB1-spiked Celufil
h 0 0.2 0.7 1.6 4.5 0.5 0.8 1.6 1.6 1.6 
Celufilf 5.5 5.3 4.8 3.9 1.0 5.0 4.7 3.9 2.8 1.7 
Proximate Composition 
(% dry matter)           
Protein 36.2 35.8 35.7 35.2 35.6 35.5 36.1 35.6 35.2 35.5 
Lipid 9.5 9.3 10.3 10.4 10.7 10.6 10.6 10.7 10.7 11.1 
Dry Matter 94.5 94.7 94.9 93.6 94.3 94.8 95.2 95.4 95.4 95 
Ash 11.1 10.9 10.9 11.3 11.1 10.9 10.9 11.1 11.8 12.9 
a Special Select, Omega Protein, Houston, TX b De-hulled, roasted/cooked and solvent extracted, Producers 
Cooperative Association, Bryan, TX c MP Biomedicals LLC, Solon, OH e Contains (as g kg-1): Ca(C6H10O6)·5H2O, 
348.49; Ca(H2PO4) 2·H2O, 136.0; FeSO4·7H2O, 5.0; MgSO4·7H2O, 132.0; K2HPO4, 240.0; NaH2PO4·H2O, 88.0; 
NaCl, 45.0; AlCl3·6H2O, 0.15; KI, 0.15; CuSO4·5H2O, 0.5; MnSO4·H2O, 0.7; CoCl2·6H2O, 1.0; ZnSO4·7H2O, 3.0; 
Na2SeO3, 0.011.
f USB Corporation, Cleveland, OH g Englehard Corporation, Jackson, MS  h Sigma-Aldrich, St. Louis, 
MO 
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of 110-L aquaria with water flowing at 1 L min-1. Biofiltration was used to maintain 
ammonia, nitrate and nitrite concentrations at non-toxic levels. Salinity was maintained 
at 7 ppt with artificial salts and water temperature was kept constant at 37 ± 2˚C by 
controlling air temperature in the wet laboratory. Supplemental aeration provided an 
adequate dissolved oxygen level of at least 80% air saturation. A 12:12 hour light:dark 
cycle was maintained throughout the conditioning and trial period and water quality was 
monitored on a daily basis. Fifteen fish (2.1 ± 0.1g) were stocked in each aquarium. The 
10 dietary treatments were randomly assigned to triplicate aquaria, requiring a total of 30 
tanks. Fish were fed a morning and afternoon ration over the course of 7 weeks. The 
diets were fed to fish beginning at a rate of 6% of the initial body weight and tapered to 
3% over the span of the trial to prevent overfeeding and to approach apparent satiation. 
The system was monitored for mortalities and any deceased fish were immediately 
removed and evaluated for cause of death.  With the exception of weight gain and 
survival which were monitored on a weekly or daily basis, respectively, all other 
parameters were evaluated at the end of 7 weeks.     
3.2.3 Fish growth and health responses 
Weight gain (% of initial weight), feed efficiency (g weight gain/ g dry diet fed), 
and survival rate (% per treatment group) were calculated at the end of the trial. Two fish 
were sampled from each aquaria and homogenized together using a blender. Whole-
body analysis was performed by evaluating moisture, ash, protein and lipid content 
according to previously established procedures  [270]. Somatic indexes including spleen, 
liver (HSI), intraperitoneal (IPF) fat and muscle (MSI) were averaged based on 2 fish per 
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aquaria (n=6). Each somatic index was calculated as follows: (organ weight/body 
weight) *100.  Only the dextral side of each fish was filleted, weighed, and then doubled 
to obtain MSI.   
3.2.4 Immunological responses 
Immunological parameters were evaluated including plasma lysozyme of white 
blood cell origin, neutrophil oxidative radical production in whole blood, and % trypsin 
inhibition. Two fish were randomly selected and bled from each tank, then pooled 
according to treatment (6 fish per treatment). A total of approximately 1-2 mL of blood 
was collected per treatment group using heparinized syringes. Plasma lysozyme was 
analyzed by employing a turbidimetric method  [274, 320]. Blood neutrophil oxidative 
radical production was measured utilizing a nitro blue tetrazolium (NBT) assay  [273, 
274]. Plasma was also used to determine % trypsin inhibition according to a previously 
established method  [321].    
3.2.5 Histological response 
Livers were dissected from two fish per tank, or six per treatment. Immediately 
after dissection, livers were fixed in 10% formalin overnight. Livers were subsequently 
rinsed with 70% ethanol solution and transferred to vials containing 10 mL fresh 70% 
ethanol. Samples were processed and paraffin embedded within 48 h for routine 
histopathology at the Texas A&M Veterinary Pathobiology Histology Laboratory 
(College Station, TX). Samples were sectioned at a thickness of 5 µm and stained with 
hematoxylin and eosin (H&E). Lesions were blindly examined and scored according to 
the criteria listed in Table 10.   
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3.2.6 Immunohistochemistry 
Immunohistochemistry for proliferating cell nuclear antigen (PCNA) was 
performed on deparaffinized sections of liver mounted on positively charged, silanized 
slides using an automated staining system for immunohistochemistry (Lab Vision 
Autostainer 360, Runcom, Cheshire, UK). Briefly, slides were placed in a heated 
chamber with DIVA decloaking solution (Biocare Medical LLC., Concord, CA) and 
heated to 121˚C for antigen retrieval. The slides were incubated with a 1:200 dilution of 
PCNA (Fisher Scientific, Walther, MA) for 20 min followed by a secondary antibody, 
ImmpRESS (Vector Scientific, Burlingame, CA) for 30 min. 
 
Table 10. Histological evaluation criteria 
Score Evaluation Description 
0 Normal Intracytoplasmic vacuolation, mostly 
macrovacuolar with one of the control livers 
also having micro and macrovesiculation. 
Nuclei are small and pushed to the periphery 
with small nucleoli. 
1+ Minimal  , Scattered increase in nuclear size and mostly 
inconspicuous nucleoli. 
2+ Mild Mild hypertrophy and pleomorphism with 
slightly prominent nuclei and more evident 
nucleoli. Some loss of intracytoplasmic 
macrovacuoles, and formation of 
microvacuoles. 
3+ Moderate Moderate cellular pleomorphism, with 
anisocytosis, anisokaryosis, megalocytosis and 
megalokaryosis. Sparse intracytoplasmic 
vacuoles. 
4+ Marked Diffuse loss of cytoplasmic vacuolation, mostly 
solid cytoplasm. Marked pleomorphism, 
anisocytosis, anisokaryosis, megalocytosis and 
megalokaryosis. 
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The primary antibody was omitted on negative control tissues. Slides were then stained 
with DAB Quanto (Vector Scientific) for 5 min, followed by counterstaining with 
hematoxylin (Biocare Medical LLC., Concord, CA) for 1.5 min. Slides were further 
dehydrated and mounted. Negative and positive control tissues were stained together 
with all fish livers. Canine and mouse small intestine, bronchial epithelium and tonsils 
were used as positive control tissues. All photographs were taken at 400X magnification.  
Stained nuclei were counted, averaged and evaluated for each treatment using 
CellProfiler software  [322]. The percentage of PCNA positive cells [(positive/total 
nuclei) x100] was calculated based on 4 fields/ fish x 6 fish/treatment (24 fields/ 
treatment). 
3.2.7 Statistical analysis 
All statistics were computed using Statistical Analysis System (SAS) version 9.2 
(SAS Institute., Cary, NC). Data from groups exposed to 0-5 ppm AFB1 were subject to 
a general linear model regression, while 0 ppm AFB1, 5 ppm AFB1, 5 ppm AFB1+1% 
NS and 5 ppm AFB1+2% NS group data were subject to an incomplete factorial 
ANOVA for all parameters except histopathological scoring. Histopathological scores 
were first subject to Aligned Rank Transformation  [323] and then further analyzed 
using a general linear model regression or incomplete factorial ANOVA. All differences 
among treatment means were determined using Duncan’s multiple range test. Treatment 
differences were considered significant at P< 0.05. 
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3.3 Results  
3.3.1 Growth parameters 
Aflatoxin B1 treatment effects, including weight gain (%), survival (%), and feed 
efficiency, did not result in linear trends, with R2 values of 0.22, 0.01 and 0.1, 
respectively. Weight gain of individual treatment means were significantly different and 
varied, with the 0 ppm AFB1 group experiencing the highest weight gain and the 2, 3, 
and 5 ppm exposure groups exhibiting the least amount of weight gain (Table 11). 
Likewise, AFB1 significantly reduced feed efficiency in a non-linear manner, with the 0 
ppm AFB1 treatment group demonstrating the highest feed efficiency (0.91) and treated 
groups ranging from 0.49-0.75. Survival also greatly varied across treatments with 0 
ppm AFB1 having the highest survival rate. 
Among the NS-supplemented treatment groups, only weight gain and feed 
efficiency were significantly different compared to AFB1 controls, with P-values of 
0.039 and 0.005, respectively. In the case of feed efficiency, 0 ppm AFB1 and 5 ppm 
AFB1 were the most significantly different. NovaSil inclusion at both 1 and 2% 
positively affected weight gain, feed efficiency, and survival after AFB1 exposure, 
although not in a dose-dependent manner. 
3.3.2 Immune response 
A summary of immune parameters evaluated for each group is shown in Table 
12. The 0.1 ppm AFB1-exposed fish exhibited the highest plasma lysozyme values (246 
units/mL), while the 5 ppm-exposed fish displayed the lowest levels (45 units/mL). 
Trypsin inhibition (%) results indicated that 1, 2, 3, and 5 ppm AFB1-exposed groups had 
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Table 11. Growth performance of red drum fed different concentrations of AFB1
1
  and AFB1 + NS 
2,3,4
 
Variable 
Weight  
gain
5
 
(%) 
Survival 
(%) 
Feed 
efficiency 
 Variable 
Weight 
gain 
(%) 
Survival 
(%) 
Feed 
efficiency 
AFB1 (ppm) Individual treatment means  AFB1 (ppm) NS (%) Individual treatment means 
0 332a 80.0a 0.91a  0 0 332.72ab 80 0.91a 
0.1 223bc 46.6b 0.62bc  5 0 188.74c 55.5 0.62c 
0.25 224bc 55.5b 0.65bc  5 1 339.80a 73.3 0.82ab 
0.5 254ab 60.0ab 0.75ab  5 2 218.50bc 57.7 0.71bc 
1 212bc 60.0ab 0.73abc  P-value 
 
0.039 0.261 0.005 
2 136c 60.0ab 0.49c  Pooled Std. Error  7.047 1.801 0.008 
3 183bc 62.2ab 0.67bc  AFB1 (ppm) NS (%) Means of main effect 
5 188bc 55.5b 0.62bc  0  332.72 80.0 0.91a 
R
2 0.22 0.01 0.1  5  249.04 62.2 0.72b 
P-value 0.005 0.132 0.03   0 260.73a 67.7 0.77 
Pooled Std. Error 5.189 1.309 0.013   1 339.88ab 73.3 0.82 
 
 
 
2 218.51b 57.7 0.71 
 
 
 ANOVA: P-values 
 AFB1  
0.083 0.138 0.003 
 NS  0.043 0.387 0.029 
1 Aflatoxin B1 
2 NovaSil 
3 Values are means of three replicate groups of fish (n=3) 
4 Values in a column that do not have the same superscript are significantly different according to Duncan’s multiple range test (P < 0.05) 
5 Initial average weight was 2.1±0.1g/fish 
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Table 12. Immune parameters of red drum1 
Variable 
Serum 
lysozyme 
(units/mL) 
NBT 
(mg/mL 
blood)
2 
Trypsin 
inhibition 
(%) 
 Variable 
Serum 
Lysozyme 
(units/mL) 
NBT 
(mg/mL 
blood)
2 
Trypsin 
inhibition 
(%) 
AFB1 (ppm) Individual treatment means  AFB1 (ppm) NS (%) Individual treatment means 
0 165ab 3.52 83.6ab  0 0 165ab 3.52 83.6 
0.1 246a 3.35 82.4b  5 0 45c 3.07 81.9 
0.25 131bcd 2.54 86.3a  5 1 76bc 3.32 81.3 
0.5 155abc 3.30 83.2b  5 2 185a 3.21 79.4 
1 106bcd 1.78 81.9b  P-value 
 
0.024 0.944 0.577 
2 82bcd 3.05 80.5b  Pooled Std. Error  5.550 0.104 0.395 
3 63cd 2.21 82.7b  AFB1 (ppm) NS (%) Means of main effect 
5 45d 3.07 81.9b  0 
 
165 3.52 83.6 
R
2 0.394 0.015 0.109  5 
 
102 3.20 80.9 
P-value 0.004c 0.250 0.038c   0 105 3.30 82.7 
Pooled Std. Error 5.705 0.102 0.192  
 
1 76  3.32 81.3 
 
 
 
2 185 3.21 79.4 
 
  
ANOVA: P-values 
 AFB1  0.018
 0.622 0.291 
 NS  0.021 0.948 0.674 
1 Values in a column that do not have the same superscript letters are significantly different according to Duncan’s multiple range test (P < 0.05).   
2 Values are means of determinations on two fish from each of three replicate groups (6 fish/ treatment, n=6).   
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Table 13. Somatic indicies of red drum fed different concentration of AFB1
1
 and AFB1+NS
2,3,4 
Variable Spleen MSI
5
 HSI
6 
IPF
7  Variable Spleen MSI HSI IPF 
AFB1 (ppm) Individual treatment means 
 
AFB1 (ppm) 
NS 
(%) 
Individual treatment means 
0 0.044 28.94 
1.678ab
c 
0.329 
 
0 0 0.044 28.9a 1.67 0.329a 
0.1 0.041 27.42 1.989a 0.116  5 0 0.043 26.0b 0.88 0.017b 
0.25 0.049 26.18 1.796ab 0.200  5 1 0.095 28.3ab 0.82 0.108b 
0.5 0.059 27.87 
1.201ab
c 
0.265 
 
5 2 0.201 29.7a 1.56 0.468a 
1 0.030 27.79 
1.155ab
c 
0.076 
 
P-value  0.528 0.031 0.292 0.003 
2 0.188 26.25 0.721c 0.187 
 Pooled Std. 
Error  
0.015 0.135 0.07 0.012 
3 0.054 25.72 
0.945ab
c 
0.067 
 
AFB1 (ppm) 
NS 
(%) 
Means of main effect 
5 0.043 26.06 0.881bc 0.017  0 
 
0.044 28.9 1.67 0.329 
R
2
 0.004 0.141 0.267 0.152  5  0.113 28 1.09 0.198 
P-value 0.503 0.417 0.091 0.466   0 0.044 27.5 1.27 0.173a 
Pooled Std. 
Error 
0.015 0.315 0.091 0.03 
 
 1 0.095 28.3 0.82 0.108a 
 
 2 0.201 29.7 1.56 0.468b 
   
ANOVA: P-values 
 
AFB1  
0.494 0.298 0.205 0.112 
 
NS 
 
0.429 0.019 0.332 0.002 
1 Aflatoxin B1 
2 NovaSil 
3 Values in a column that do not have the same superscript letters are significantly different according to Duncan’s multiple range test (P < 0.05).   
4 Values are means of determinations on two fish from each of three replicate groups (6 fish/ treatment, n=6).   
5 Muscle somatic index 
6 Hepatosomatic index 
7 Intraperitoneal fat
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the lowest percent inhibition and 0.25 ppm AFB1 the highest. Additionally, neither the 
lysozyme nor the trypsin results suggested linearity with an R2 of 0.3947 and 0.109, 
respectively. The NBT test showed no significant differences among any of the AFB1-
exposed groups.  NovaSil had a significant impact (P = 0.021) on the plasma lysozyme 
concentration with 5 ppm AFB1+2% NS outperforming all other treatments. NovaSil did 
not significantly alter levels of NBT or trypsin inhibition.        
3.3.3 Somatic indexes 
Somatic indexes for spleen, MSI and IPF did not vary within the AFB1-treated groups; 
however, HSI varied slightly between treatments. The highest HSI levels were recorded 
in the 0.1 AFB1-treated group, while the 2 ppm and 5 ppm exposure groups exhibited the 
lowest values (Table 13). A linear trend was not present in any of the groups. In the NS-
supplemented groups, muscle and IPF levels recovered to control levels in the treatment 
group administered 2% NS. Likewise, the means of main effect data indicate that NS 
inclusion at either 0 and 1% was statistically different than 2%.   
3.3.4 Proximate composition  
No linear trends were present in the AFB1-treated groups (Table 14). Percent 
lipid composition was highest in the 0 ppm AFB1 group and the lowest at 2 ppm AFB1, 
but varied among other treatments.  There were some variations in ash values as well; 
however, these results were not linearly correlated. Inclusion of NS in the diets did not 
exhibit any statistically significant changes in whole-body proximate composition.  
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Table 14. Proximate composition of red drum (fresh-weight basis)1 
Variable 
% 
Lipid 
% 
Protein 
% 
Moisture 
% 
Ash 
 Variable 
% 
Lipid 
% 
Protein 
% 
Moisture 
% 
Ash 
AFB1 (ppm) Individual treatment means  AFB1 (ppm) NS (%) Individual treatment means 
0 2.70a 76.01 78.38 16.38ab  0 0 2.21 76.01 78.30 3.54 
0.1 2.37ab 74.45 79.34 17.56a  5 0 1.98 76.52 79.29 3.73 
0.25 1.97bcd 70.06 79.67 13.64b  5 1 2.20 73.92 76.91 4.28 
0.5 2.42ab 74.33 77.69 16.72ab  5 2 2.19 72.93 79.04 4.35 
1 2.17abc 71.64 78.71 18.04a  P-value  0.510 0.723 0.173 0.629 
2 1.45d 74.20 84.55 19.43a  Pooled Std. Error  0.022 0.488 0.140 0.098 
3 1.77cd 71.64 80.60 17.22a  AFB1 (ppm) NS (%) Means of main effect 
5 1.98bcd 76.52 79.29 18.02a  0 
 
2.21 76.01 78.38 3.54 
R
2
 0.211 0.021 0.024 0.109  5 
 
2.12 74.46 78.41 4.12 
P-value 0.002 0.476 0.452 0.038   0 2.10 76.20 78.83 3.64 
Pooled Std. Error 0.033 0.441 0.402 1.728   1 2.20 73.90 76.91 4.28 
  2 2.19 72.90 79.04 4.35 
   
ANOVA: P-values 
 
AFB1  
0.534 0.611 0.964 0.357 
 
NS 
 
0.394 0.604 0.095 0.663 
1Values are means of determinations on three fish from each of the three replicates (n=3).  
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Figure 10. Liver histopathology in AFB1-exposed red drum. Liver sections were stained with hematoxylin and eosin. Treatments were as 
follows: A) 0 ppm AFB1 B) 1 ppm AFB1 C) 3 ppm D) 5 ppm AFB1 E)AFB1+ 1% NS and F) 5 ppm AFB1 +2% NS. Marked 
pleomorphism, megalokaryosis with prominent nucleoli (arrows) and loss of hepatocellular cytoplasmic macrovacuolation was observed 
in the treatment groups that received large amounts of aflatoxin (B,C,D). Although not significant, inclusion of NS resulted in decreased 
histopathological scores, especially attributed to increased cytoplasmic vacuolation and reduced cellular pleomorphism.     
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Figure 11. Proliferating Cell Nuclear Antigen (PCNA) positive cells in red drum hepatocytes. Liver sections were stained with PCNA 
(arrows) and hematoxylin counterstain. Treatments were as follows: A) 0 ppm AFB1 B) 1 ppm AFB1 C) 3 ppm AFB1 D) 5 ppm AFB1 E) 
5 ppm AFB1+ 1% NS F) 5 ppm AFB1+ 2% NS. Although not significant, inclusion of NS resulted in a decrease of PCNA-positive 
hepatocytes. Reduction in cell proliferation suggests that NS afforded some protection from AFB1 toxicity and cellular proliferation.    
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3.3.5 Histopathological response and immunohistochemistry 
Significant histological changes were observed between treatments (Table 15), 
with 3 and 5 ppm AFB1 eliciting the most severe hepatic alterations. Although some 
samples revealed significant hepatic lesions in groups treated with 5 ppm AFB1 + 1 or 
2% NS, the findings in these fish were considered mild when compared to the 5 ppm 
AFB1 without NS. There were no significant differences in PCNA values among all 
treatments, nor did PCNA staining exhibit a positive linear correlation. Histological 
changes, characterized by restoration of hepatocellular macrovacuolation and reduced 
megalocytosis and karyomegaly, were noted with the addition of NS in the diet; 
however, these results were not statistically significant (Figure 10).  A decrease in 
PCNA staining as compared to the 5 ppm inclusion level was noted, but also did not 
achieve significant levels with 1 or 2% NS inclusion in the diet (Figure 11).  
3.4 Discussion 
Aflatoxin B1 displayed a significant effect across multiple treatment levels. The 
survival rate for the basal diet group (0 ppm AFB1) was similar to control survival 
results reported in other red drum studies  [324, 325], although survival was negatively 
affected by AFB1 presence. Likewise, the impact on feed efficiency and weight gain 
found in this study has been similarly documented in other AFB1-exposure publications, 
including research analyzing the effects of aflatoxins on several different farmed aquatic 
species  [83, 326, 327, 328, 329]. The majority of AFB1-sensitive ichthyoids are cold-
water species and our findings suggest that red drum may be one of the first identified 
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Table 15. Histopathology and immunohistochemistry 
Variable 
Histology 
Score
1 PCNA 
 
  Variable 
Histology 
Score 
PCNA 
AFB1(ppm) 
Individual treatment 
means 
 
AFB1(ppm) NS (%) 
Individual 
treatment means 
0 5.25a 6.27  0 0 13.16ab 6.27 
0.1 10.67a 8.59  5 0 19.00b 10.49 
0.25 17.33ab 9.35  5 1 9.16a 9.11 
0.5 30.16c 11.34  5 2 7.66a 9.72 
1 25.83bc 9.52  P-value  0.0925 0.7542 
2 31.83c 9.06  Pooled Std. Error 
 
0.838 0.836 
3 37.00c 10.30  AFB1 (ppm) NS (%) Means of main effect 
5 37.00c 10.49  0  13.16 6.27 
R
2 0.2353 0.0204  5  11.94 9.78 
P-value 0.0001 0.5059   0 16.08 8.38 
Pooled Std. Error 1.13 0.8159   1 9.16 9.11 
 
 2 7.66 9.72 
   
ANOVA: P-values 
 
AFB1  
0.7248 0.3251 
 
NS 
 
0.0491 0.9454 
1 Values in a column that do not have the same superscript letters are significantly different according to Duncan’s multiple  
range test (P < 0.05).
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AFB1- sensitive warm-water species. However additional studies are necessary to 
determine the specific metabolic mechanisms responsible for this sensitivity. The 
published aquaculture literature indicates that incremental increases in AFB1 exposure 
do not typically result in dose-dependent, linear responses [90, 91, 97]. Herein, analysis 
of growth performance factors indicated that some of the most significant AFB1 effects 
were present at the lowest level of AFB1- exposure (0.1 ppm) for feed efficiency, 
survival, and weight gain. Hormetic responses for growth and immunological parameters 
have been observed in several species  [330]. Hormesis is defined as a biphasic response 
to an xenobiotic, characterized by a low-dose stimulatory effect and high-dose inhibitory 
or toxic effect in which a U-shaped or J-shaped model is apparent  [331]. Instances of 
AFB1-associated hormesis have also been documented in multiple species  [332, 333, 
334]. Several measured parameters in the current study suggest that AFB1-exposed red 
drum exhibited an “inverted U-shaped” immunological hormetic response to AFB1 as 
suggested by plasma lysozyme at the 0.1 ppm level and trypsin inhibition at the 0.25 
ppm level. Additionally, HSI results indicated a similar increase at the 0.1 ppm level 
followed by subsequent decreases at higher AFB1 levels. 
Several studies have indicated that PCNA is a suitable marker for cellular 
proliferation in fish  [335, 336] as well as other species  [337, 338]. However, our study 
did not indicate any significant differences in PCNA staining among the treatments. It is 
possible that the levels of AFB1 used in this study were not capable of inducing 
significant cellular proliferation as observed with other species. While there was a slight 
increase in PCNA with the presence of AFB1, there was a decrease in HSI.  The increase 
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in PCNA is due to liver damage and mitotic activity from AFB1-exposure, while the 
overall decrease in HSI is likely attributed to the loss of vacuolation and fat in the liver. 
Histological evaluation indicated liver changes characterized by anisokaryosis, 
megalocytosis and karyomegaly in AFB1-exposed red drum, which have been noted in a 
series of AFB1 studies with other fish species  [42, 339, 340]. Hepatocellular lipid 
deposition, a well-documented classical sign of aflatoxicosis in fish  [341, 342], was 
present in red drum exposed to AFB1. However, red drum kept in captivity typically 
display fatty deposition and hepatocellular macrovacuolation [343], which should be 
taken into consideration for accurate red drum liver evaluation.  The hepatocellular 
vacuolation seen in control livers was markedly reduced, as anisocytosis and 
karyomegaly increased, especially in fish exposed to higher levels of aflatoxin. 
Interestingly, hepatocellular vacuolation and liver fat were restored in fish treated with 
NS. Ideally, further red drum AFB1 studies should pair liver histological evaluation with 
other molecular markers to confirm liver damage, such as inducible nitric oxide synthase 
( [344] or γ-glutamyl transpeptidase  [345, 346]. Additionally, because feed efficiency, 
IPF and liver fat decreased with AFB1 exposure, it is possible that there was increased 
energy expenditure in the fish because less food was utilized.  However, more research 
is needed to determine the exact mechanism of fat loss in AFB1-exposed red drum.    
 In this study, NS supplementation in the diets of AFB1-exposed fish resulted in a 
protective effect, which was evident by the significant improvement in many of the 
tested parameters.  Other studies have reported that a 2% inclusion level of bentonite, a 
common clay containing montmorillonite, in trout feed reduced toxic AFB1 
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effects  [112]. Yet other studies suggest that a 0.5% inclusion level was sufficient to 
protect tilapia from 1.5 ppm AFB1  [340]. Bentonites have been added into fish feed at 
concentrations up to 10% with no alteration in whole-body proximate 
composition  [347]. Discrepancies in the aquaculture literature concerning the proper 
inclusion level of clay-based binders indicate a need to establish a clay dosing regimen 
for fish at risk for AFB1 exposure.      
3.5 Conclusions   
These findings indicate that red drum are susceptible to AFB1 in levels as low as 
0.1 ppm. Other unevaluated species should be tested for AFB1 susceptibility, especially 
warm-water species raised in tropical and subtropical environments where the 
mycotoxin contamination risk is high. NovaSil supplementation at levels between 1-2% 
may be used in fish feed safely to effectively reduce AFB1 toxicity. Therefore, this 
technology could be used by the aquaculture industry as a strategy to reduce aflatoxin-
related morbidity and mortality in fish.   
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4. NOVASIL AS A THERAPY FOR TNBS-COLITIS: A ONE-WEEK PILOT 
STUDY 
4.1 Introduction 
Inflammatory bowel disease (IBD) is currently the leading gastroenterological 
condition that is increasing healthcare expenses in the United States. Direct medical 
costs related to CD total an average of $18,000 per patient per year  [348]. Current 
therapies for CD are contributing to these excessive costs and often leave patients with 
side effects such as increased suceptibility to infectious disease and increased risk for 
certain types of cancer and nervous system disorders  [217]. Further investigation of 
alternative therapies to supplement or replace conventional treatments is warranted. 
While NovaSil (NS) has historically been used as an anti-caking agent and more 
recently, a mycotoxin binder  [116, 118], little is known about its anti-inflammatory 
effects or capability to reduce histopathology in the gastrointestinal tract of an IBD 
patient. Studies suggest that similar clays have been successfully used to treat infectious 
diarrhea  [349] and can alleviate certain IBD effects in rodent models  [153]. However, 
factors such as proper dose, method of administration, and efficacy in mitigating active 
disease and/or maintaining a state of remission  have yet to be determined.   
The TNBS colitis murine model is one of the most commonly used models for 
CD research. It is characterized by a Th1/Th17 cytokine profile and transmural (patchy) 
inflammation along the GI tract. In this model, rodents under sedation are intrarectally 
injected with a mixture of TNBS/EtOH or PBS/EtOH.  After injection, TNBS haptenates 
colonic proteins with trinitorphenyl which causes an inflammatory immune response. 
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Advantages of the TNBS colitis model are that it is highly reproducible and it produces 
similar CD-like immune and histopathological effects.  
The purpose of this study was to provide preliminary data to determine the 
therapeutic benefit of NS at a 2% inclusion rate in the TNBS colitis model. Feed 
rejection, colitis symptoms and inflammatory endpoints were assessed.  
4.2 Materials and methods 
4.2.1 TNBS colitis model 
Five-wk old female BALB/c mice were ordered from The Jackson Laboratory 
(Bar Harbor, Maine) and acclimated for 1 week at the Comparative Medicine Program 
(CMP) building according to the animal use protocol approved by Texas A&M 
University (TAMU). Four mice were randomly assigned to each cage. Additional 
bedding was added into the cages and shallow feeding bowls were implemented to 
increase comfort and to better maintain hydration level. Feed was moistened with a 
small amount of H2O to prevent dehydration during episodic diarrhea. A constant 
temperature (23°C) and a 12 hr. light:dark cycle were implemented in the room where 
animals were housed. Mice were randomly assigned to one of three treatment groups: 
Control, TNBS or TNBS+NS.  
Before induction, mice were lightly anesthetized with isofluorane gas in a small 
chamber. A 4-cm oral gavage tip was used for intrarectal dosing and surgical lubricant 
was applied to the tip. Once the mice were sedated, they were quickly removed from the 
chamber and intrarectally injected with 150 uL of TNBS/EtOH or PBS/EtOH. Mice 
were secured vertically in a “recovery” chamber to ensure thorough distribution and 
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retention ofTNBS/EtOH orPBS/EtOH in the colon. Mice were induced on day 1 of the 
study and euthanized on day 7.  
4.2.2 Weight gain and somatic indexes 
Mice were collectively weighed according to each cage.  Weights were recorded 
at three different timepoints: immediately before intrarectal injection, at 3 days,  and at 
the end of the week (prior to euthanasia). Somatic indexes were calculated using the 
following equation: (organ weight/ body weight)*100. 
 
Table 16. Histopathological criteria   
Feature Description Scores 
Inflammation extent None 0 
  mucosa 1 
  mucosa+submucosa 2 
  transmural  3 
Damage in crypt architecture None 0 
  hyperplasia/regeneration 1 
  destruction 2 
Hyperemia/edema without 0 
  With 1 
Infiltration with inflammatory cells without 0 
  Mild 1 
  moderate 2 
  Severe 3 
Ulceration None 0 
  focal/mild 1 
  multifocal/severe 2 
 
4.2.3 Histopathology 
Immediately following euthanasia, the intestines were collected from each mouse 
and flushed with PBS. Transverse cross sections were cut in 1-cm sections, stored in 
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10% formalin, and allowed to fix overnight. Intestines were embedded within 24 h. for 
histopathology at the Texas A&M Veterinary Pathobiology laboratory. Samples were 
sectioned at 5 µm and stained with hemotoxylin and eosin.  Histopathology scoring was 
performed by Dr. Aline Rodrigues Hoffmann according to the criteria listed in Table 16.   
4.2.4 C-reactive protein 
Upon CO2 euthanasia, mice were exsanguinated via cardiac puncture. Blood was 
allowed to separate for 3 h, and subsequently centrifuged. Serum and collected and 
stored at -20˚C. C-reactive protein (CRP) was detected in the serum using ELISA 
(SABiosciences) using serum samples run from each individual mouse.  
4.3.5 Statistical methods  
JMP software (SAS Institute) was used to analyze all statistics for the study. All 
data were subject to ANOVA and data were considered significant at P<0.05. A post-hoc 
Student’s t-test was performed for all parametric data and a Wilcoxson test was 
employed for non-parametric data.  
4.3 Results 
4.3.1 Weight gain, somatic indexes and inflammation 
There were no significant changes in weight loss or somatic indexes during the 
one week study (Figure 12). However, the TNBS group experienced the greatest weight 
loss followed by TNBS+NS. It was also noted that there was a slight weight decrease in 
the Control group, possibly due to the temporary lack of appetite following intrarectal 
injection and sedation. Colon length slightly decreased in the TNBS group, compared to 
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Figure 12. Physiological parameters. Weight loss, colon length, hepatosomatic index and C-reactive protein were examined at 
the end of 1 week. While results were not significant, colon length decreased slightly with the presence of TNBS.  
Additionally, weight loss decreased in the TNBS group, but was less severe in the TNBS+NS group.   
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Figure 13. Control and colitis intestinal histopathology. A) Control intestinal tissue demonstrating uniform crypt structure and 
healthy lamina propria B) Coltis tissue demonstrating mucosal inflammation and distortion of crypt architecture  
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the Control and TNBS+NS groups, however this trend did not exist for  hepatosomatic 
index values. C-reactive protein levels non-significantly increased in the TNBS group, 
but TNBS+NS group samples exhibited levels that more closely resembled those of the 
control group.  
4.3.2 Histopathology  
Results indicate that there were no significant differences between treatments 
based on histopathological scoring (P=0.43) (Figure 13). Colitis was successfully 
induced in mice exposed to TNBS, however the severity of colitis varied substantially 
between individual mice. Mice in the TNBS or TNBS+NS groups showed signs of 
inflammation and edema in the intestine. Damage to crypt architecture was the most 
prominent finding from TNBS group, while mice in the TNBS+NS group demonstrated 
less severe crypt damage. Control tissues demonstrated mild histopathology, most likely 
due to the intrarectal injection procedure. NovaSil did not appear to have any significant 
effect on histopathological scores.  
4.4 Discussion 
The purpose of this pilot study was to explore the anti-inflammatory effects of 
NS in vivo.  Trends resulting in improvement in weight gain, decrease in CRP, and 
increased colon length with NS supplementation in the feed indicated that NS may 
provide protection. Other researchers determined that feed efficiency and weight gain 
were improved solely with clay supplementation in chickens and pigs  [350]. 
Additionally, clay-based supplementation improved weight gain and post-weaning 
diarrhea in young pigs  [351]. Furthermore, children suffering from infectious diarrhea 
102 
 
benefit from oral clay therapy. In a 2001 Italian study with over 800 children, smectite 
demonstrated a significant decrease in the duration of diarrhea, improved stool 
consistency and decreased frequency of bowel movements.  [138].  Several other rodent 
study investigators have administered clay therapy using oral gavage. Although oral 
gavage is an acceptable method to administer therapeutics, mice did not demonstrate 
feed rejection with 2% NS inclusion in the diet. Therefore, NS administration via feed 
inclusion appears to be an acceptable method of dosing. Avoiding gavage in a mouse 
model involving intrarectal injection is advantageous, considering that consecutive 
intrarectal injections and gavages would likely cause excess physiological and 
psychological stress.   
Based on the results of this study, some minor improvements are warranted for 
future in vivo colitis experiments. Histopathology did not coincide with the other results 
obtained including weight gain, CRP and colon length. This may be attributed to the 
manner in which the colon tissue was collected. Sections were sampled transversely and 
only revealed a small subsection of the entire length of the colon. Due to transmural 
ulceration in CD, it is possible that the transverse cross sections did not reflect the 
amount of ulceration that was present throughout the entire length of the colon. Future 
studies may either need to alter collection of colon samples or utilize indirect methods to 
assess intestinal damage and inflammation, rather than rely on histopathology. 
One-hundred and fifty µL is the standard fluid volume of TNBS administered to 
mice, based on the previously published TNBS colitis protocol  [201]. In this study, the 
5-wk-old BALB/c mice induced with 150 µL exhibited symptoms of excess induction. 
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Subsequently, three out of the eight mice died (38%) in the first 4 days in both the TNBS 
and TNBS+NS groups. Some studies have reported up to 60% mortality after 1 
week  [352, 353]. Additionally, the volume was most likely too large and the mice 
tended to release a portion of the fluid, leading to some inconsistency in dosing.  Future 
studies will incorporate a smaller volume for more accurate dosing and to avoid loss of 
the TNBS. Additionally, since therapeutic treatment did not yield significant results, 
prophylactic administration of NS will be administered in future studies at a higher 
dosage and the length.  A longer study is warranted to determine if more time would 
provide more beneficial therapeutic effects.   
4.5 Conclusions 
This study suggests that NovaSil may be a promising therapy for TNBS-induced 
colitis. Though not significant, NS improved weight gain, CRP levels, and colon length. 
This study also provided valuable information that will improve future studies. Finally, 
an in vitro investigation that will evaluate the mechanism behind NS-based IBD therapy 
is needed.  
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5. MITIGATION OF TNBS-INDUCED COLITIS WITH NOVASIL THERAPY 
5.1 Introduction 
Crohn’s disease (CD) is characterized by painful ulceration that can occur along 
the gastrointestinal tract, from the mouth to the anus, as opposed to ulcerative colitis 
(UC) which is restricted to the colon  [354].  The majority of cases occur in the 
developed world, similar to other autoimmune diseases.  Although the etiology of CD is 
complex, genetic polymorphisms, alterations in intestinal microbiota, and a modulated 
immune response have all been attributed to possible causes of the disease. Additionally, 
cigarette smoking, excess stress and environmental factors are known to play a role in 
the progression of the disease  [355, 356, 357].  Treatments for CD can be expensive and 
often cause undesirable side effects  [358, 359]. Common pharmaceutical treatments 
include aminosalicylates, antibiotics, corticosteroids, and biologics (anti-TNFα 
agents)  [360]. Immunosuppressive treatments often involve increased risk of infection 
and certain types of cancer, such as lymphoma  [361]. Due to various risks associated 
with these medications, there is a need to develop alternative therapies. Diarrhea caused 
by various gastrointestinal (GI) conditions can be mitigated by dietary clays. 
Historically, DS clays have been utilized effectively for the treatment of diarrhea caused 
by infectious diseases  [138, 139, 362]. From these studies, it can be most easily 
speculated that clay treatments are capable of pathogen or toxin sorption. However, DS 
has also been shown to increase mucosal barrier integrity against pepsin and TNFα 
exposures in vivo  [363, 364], and to provide protection from immune system 
disturbances induced in guinea pigs sensitized to cow’s milk  [365]. Moreover, 
105 
 
inflammation occurring as a result of acute hapten exposures decreased following 
treatment with dietary clays  [153].  
Although the specific mechanisms of action have yet to be reported in the case of 
chronic diarrhea, several theories have been proposed that may support the therapeutic 
nature of smectite clays, including the possibility of intestinal mucus barrier 
reinforcement (reducing penetration of luminal antigens) and modulation of pro-
inflammatory cytokine production and effects. Of particular importance is the intestinal 
barrier, which is affected by the presence of luminal inflammatory cytokines, such as IL-
6, IL-1β, and TNFα  [366]. In the absence of bacterial or viral infection, malfunction of 
the intestinal barrier is pivotal in diseases causing chronic diarrhea, such as IBD  [367]. 
Additionally, DS clays have demonstrated the potential to shift the population of 
intestinal flora from a pathological to a balanced state  [158, 368, 369], which is known 
to be important in the etiology and management of IBD  [192, 370]. Furthermore, in 
vitro and in vivo studies have indicated that smectite clays can form aggregates with E. 
coli  [371, 372]. Copper-bearing montmorillonite decreased E. coli and Clostridium 
counts in the intestine of male broilers and also improved intestinal mucosal 
morphology  [159]; however, no studies have profiled the intestinal microbiome in 
smectite-supplemented animals  
NovaSil (NS), a calcium montmorillonite clay with a dioctahedral structure and 
negatively charged interlayer, has been administered as a supplement both in animal 
feeds and in clinical intervention trials throughout the world to reduce dietary mycotoxin 
bioavailability  [373].  Currently, little information is available concerning the potential 
106 
 
NS anti-inflammatory properties or its impact on gut microbiota.  Similar clays have 
been reported to possess anti-inflammatory properties, but the mechanism remains 
unclear  [153, 374, 375].  For this reason, we investigated the ability of NS to interact 
with proinflammatory cytokines, protect the intestinal microbiota, and mitigate colitis.  
The pH of the normal colon ranges between 6.5 and7.6. Comparatively, the 
colonic pH in an individual with CD is approximately 5.3 [376], but can drop to a pH of 
0.6 in a patient with severe disease. [377].  Based on the fact that the isoelectric point of 
TNFα is 6.4±0.3  [378], it is expected that TNFα is protonated in individuals living with 
CD.  Likewise, the isoelectric point of proinflammatory IL-1β lies between 6.1 and 
6.9  [379], and is increasingly protonated as pH becomes more acidic. This suggests that 
negatively charged NovaSil could sorb protonated proinflammatory cytokines at a low 
pH. NS has a long-standing record of safety and efficacy and does not interfere with 
vitamin or nutrient levels in the serum. If NS demonstrates anti-inflammatory effects in a 
TNBS model, then it may prove an effective model for CD.  
The purpose of this study was two-fold: 1) to characterize the NS-cytokine 
interaction in vitro, and 2) to determine the ability of NS to reduce colitis-related effects 
and counteract dysbiosis in a TNBS-mouse model.  
5.2 Materials and methods 
5.2.1 ELISA-based assessment of in vitro binding affinity   
Deionized H2O was adjusted to pH 5 to simulate the intestinal pH that would 
likely be present in diseased intestine. Recombinant TNFα and IL-1β protein (Sigma-
Aldrich, St. Louis, MO) were added to the pH-adjusted H2O in borosilicate glass vials, 
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resulting in a protein concentration of 210 pg/mL in each vial. Additionally, NS ranging 
from 0 to 400 µg/mL was added to the vials.  To determine if protein was primarily 
bound to internal or external clay surfaces, interaction with both intact and heat-
collapsed NS was investigated. Heat-collapsed NS was synthesized according to a 
previously published method  [380].  The interlayer contributes to the majority of 
negative charge of the NS structure  [381]. Collapsing the structure of NS results in 
elimination of H2O from the interlayer as well as dehydroxylation of the clay. Briefly, 
NS was heated in a furnace for 30 min. at 200ᵒ C and then at 800ᵒC for 1 h. The intact 
and heat-collapsed NS were then separately added to individual vials. The protein was 
maintained at a constant concentration (210 pg TNFα or IL-1β) and total volume 
adjusted to 1 mL per vial with H2O.  Controls included one vial for H2O only, diluted 
protein only and H2O+each concentration of NS. The vials were incubated at room 
temperature on an orbital shaker operating at 100 rpm for one hr.  The vials were then 
removed from the shaker and centrifuged at 2000 rpm for 20 minutes.  The supernatant 
was pipetted and separated from the NS pellet at the bottom of the tube and measured 
via ELISA for TNFα and IL-1β. The NS pellet was resuspended in H2O, incubated, 
centrifuged as described above, and subjected to cytokine detection by ELISA.  This 
procedure was used to determine the amount of unbound protein in the supernatant. 
Protein concentrations were calculated based on a standard calibration curve.   
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5.2.2 Transmission electron microscopy (TEM) and powder x-ray diffraction 
(XRD) 
Samples containing 1 µg TNFα/100 µg NS or 1 µg IL-1β/100 µg NS were 
prepared for TEM in order to further characterize the protein-NS binding interaction. 
Samples were dehydrated using an ethanol series followed by propylene oxide.  Samples 
were further embedded in epoxy-resin, sealed with epoxy, and cured at room 
temperature for 24 h, as described by Kolman et al.  [382].  Samples were sectioned into 
60-100-nm slices. All images were imaged with a Morgagni (FEI) Transmission 
Electron Microscope at 80 kV (FEI Company, Hillboro, OR).  Diffractograms were 
recorded for NS, heat-collapsed NS, NS+IL-1β and NS+TNFα.  A 1-cm-diameter o-ring 
was coated with a thin layer of petroleum jelly and suctioned onto a custom-made zero 
background holder.  Samples (1000 µg: 1 µg protein/ 100 µg NS) were drop-casted onto 
the holder.  A Bragg-Brentano powder short-arm diffractometer (Bruker Coorperation, 
Billerica, MA) was used for all diffraction patterns (λ=0.1540 nm) within the 2θ range of 
2ᵒ to 20ᵒ, with a 0.014ᵒ step size.  Bragg’s Law (nλ=2dsinθ) was used to calculate the d-
spacing between the smectite layers.  
5.2.3 TNBS induction of Crohn’s colitis in mice 
Five-wk old BALB/c mice were purchased from the Jackson Laboratory (Bar 
Harbor, Maine) and housed at the Comparative Medicine Program (CMP) facility at 
Texas A&M University. To increase animal comfort following the TNBS induction 
process, extra bedding was added to the cages, and powdered feed was moistened with 
H2O and made accessible in low ceramic bowls. A 12:12 h light:dark cycle and a stable 
temperature (23°C) were maintained in the room where the animals were housed.  
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TNBS induction of colitis, an established model for CD, was utilized as 
previously described  [201] with slight modifications.  Forty mice were equally and 
randomly allocated into four different treatment groups: Control (Control) (n=10), 4% 
NS supplementation (NS) (n=10), TNBS-induced (TNBS) (n=10), and TNBS induction 
with 4% NS supplementation (TNBS+NS) (n=10).  Mice in the TNBS+NS and NS 
groups were conditioned with the 4% NS diet for 1 week prior to the beginning of the 4-
week trial.   One-hundred µL of 1:1 TNBS:ethanol was intrarectally administered to the 
TNBS and TNBS+NS groups with a 4-cm gavage tip. Control and NS groups received 
100 µL of 1:1 phosphate buffered saline (PBS):ethanol using the same technique on a 
weekly basis. To ensure retention of all solutions throughout the colon, mice were 
secured vertically in a recovery chamber for 1 min while anesthetized.  Mice that were 
severely symptomatic (bloody diarrhea, lethargy, impaired motor skills) or exhibited 
severe weight loss (>25% initial body weight) were immediately euthanized. Mice were 
induced on a weekly basis, and sacrificed at the end of 4 weeks via CO2 asphyxiation. 
This research was approved by the Institutional Animal Use and Care Committee at 
Texas A&M University, College Station, TX.     
5.2.4 Weight gain and final somatic indexes 
Mice were weighed on an individual basis twice per week and monitored on a 
daily basis. Following euthanasia, selected organs, including the liver and 
gastrointestinal tract, were collected and weights, as well as colonic length were 
recorded.  Colon weight:length ratio was calculated in addition to hepatosomatic index 
(HSI) ((liver weight (g)/weight of the mouse)*100).  
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5.2.5 Serum ELISA 
Blood (1 mL) was collected from mice via cardiac puncture immediately 
following euthanasia.  Whole blood was allowed to separate for approximately 3 h at 4ᵒ 
C.  Blood was subsequently centrifuged and serum was stored at -20ᵒ C.  Circulating 
levels of inflammatory proteins were examined using a Mouse Th1/Th2/Th17 cytokine 
Multi-Analyte ELISArray Kit (MEM-003A, Qiagen, Valencia, CA, USA).  Serum was 
pooled according to treatment group and relative expression of the following cytokines 
was assayed in triplicate: IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, IL-13, IL-17A, IL-23, 
IFNγ, TNFα, TGF-β1.      
5.2.6 C-reactive protein  
Serum C-reactive Protein (CRP) levels were quantified for all treatment groups. 
Serum CRP was detected using an ELISA kit (Genway Biotech Inc., San Diego, CA, 
USA). Serum from four mice per group was used with six replicates per mouse.  
5.2.7 DNA extraction and gut microbiota sequencing 
Feces were collected from the colon following euthanasia. Samples were “flash 
frozen” in liquid nitrogen, and subsequently transferred to a -80°C freezer until further 
use. Samples were thawed and genomic DNA was extracted using the Power Soil DNA 
isolation kit (MoBio Laboratories). Six randomly selected fecal samples were selected 
from the Control, TNBS and TNBS+NS groups. The V4 region of the 16S rRNA gene 
was amplified with primers 515F (5’-GTGCCAGCMGCCGCGGTAA-3’) and 806R 
(5’-GGACTACVSGGGTATCTAAT-3’) at the MR DNA Laboratory (Shallowater, TX, 
USA). PCR amplification products were verified on 2% agarose gels and samples were 
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purified using calibrated Ampure XP beads. The Illumina TruSeq DNA Library was 
used to prepare a DNA library and sequenced at MR DNA on an Illumina MiSeq 
instrument.  
5.2.8 Microbiome data analysis 
Quantitative Insights Into Microbial Ecology (QIIME, v.1.8) software was used 
to phylogenetically characterize the samples. The raw sequence data were demultiplexed 
by barcodes, and low quality reads were filtered using the QIIME database’s default 
parameters. A total of 824,894 (median: 45,474; range 37,692 – 54,975 sequences per 
sample) were obtained. For further analysis, each sample was rarefied to an even 
sequencing depth of 32,700 sequences per sample to adjust for uneven sequencing depth 
across all samples. Sequences were then clustered into operational taxonomic units 
(OTUs) using a closed-reference OTU picking protocol at the 97% sequencing identity 
level using UCLUST   [383] against the Greengenes database   [384] pre-clustered at 
97% sequence identity  [385]. Proportions of bacterial taxa (% of total sequences) were 
statistically evaluated using a Kruskal-Wallis test, where appropriate, and corrected by 
multiple comparisons using the Benjamini & Hochberg’s False Discovery Rate. P values 
<0.05 were considered statistically significant. Observed species richness, Chao 1, and 
Shannon indexes were all determined using alpha-diversity parameters within QIIME.  
Beta-diversity analysis was determined using Principal Coordinates Analysis 
plots (PCoA) and unweighted Unifrac distance metrics. Statistical significance of the 
resulting distance matric was tested by analysis of similarities (ANOSIM) using the 
QIIME software  [386].  
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5.2.9 Statistical analysis 
Aside from microbiome data, all other data were subject to a one-way ANOVA 
followed by a Student’s t-test for parametric data. Non-parametric data was subject to 
Wilcoxon rank-sum test. All statistics were analyzed with the assistance of JMP software 
(SAS Institute, Cary, NC, USA). Values were considered significant at P < 0.05. Data in 
graphs are expressed as the mean +/- std. error.  
5.3 Results 
5.3.1 In vitro cytokine-NS interaction  
Results indicate that 200 µg NS sorbed 90% of TNFα (190 pg/mL) and 76% of 
IL-1β (161 pg/mL) after two washes (Fig. 14).  Collapsed NS sorbed only 21% of TNFα 
(44 pg/mL) and 9% of IL-1β (18.9 pg/mL).  The highest concentration of NS (400 
µg/mL) did not bind more TNFα than the 200 µg/mL concentration (189 pg/mL). NS at 
concentrations from 100- 400 µg/mL bound the same amount of IL-1β (161 pg/mL). 
Heat-collapsed NS at concentrations ranging from 50 μg/mL to 400 μg/mL sorbed equal 
amounts of IL-1β and TNFα bound.   
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Figure 14. Adsorption of proinflammatory cytokines onto NovaSil (NS). TNFα and IL-
1β are sorbed onto the surface of NS (0-400 µg) as determined by ELISA.  Upon 
interlayer collapse of NS by heat, sorption of TNFα and IL-1β onto NS is substantially 
(p=0.0001) reduced.  
 
5.3.2 XRD and TEM  
X-ray diffraction yielded results (Fig. 15) that were consistent with Fig. 14, 
suggesting apparent expansion of NS interlayers in the presence of protein. X-ray 
diffraction can be used to measure the distance (d-spacing) between each atomic plane in 
the clay mineral.  Results indicated that both TNFα+NS (d=13.6) and IL-1β+NS 
(d=13.88) exhibited increased d-spacing when compared to the control NS sample 
(d=13.13).  Heat-collapsed NS did not exhibit the typical montmorillonite peak upon 
XRD analysis, confirming a lack of interlayers in the structure. Transmission electron 
microscopy images of the intact clay indicated a very tight interlayer structure (Fig. 2B), 
compared to TNFα+NS and IL-1β+NS.  Images taken from the TNFα+NS and IL-
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1β+NS samples suggest that the interlayers within the clay structure expand in the 
presence of protein (Fig. 15C and 15D).    
5.3.3 Weight gain and final somatic indexes  
Body weight decreased significantly in the TNBS-treated mice after the first 
induction.  NovaSil did not significantly alleviate weight loss until the second wk 
compared to the TNBS group and the greatest difference in weights between the 
treatment groups was observed after the final induction.  The TNBS group exhibited 
statistically significant, severe weight loss in the fourth wk of the study. Colon 
weight:length ratio significantly differed between groups (p=0.05), with the TNBS group 
having the largest weight:length ratio. Colon weight:length ratio in NS-supplemented 
mice was not significantly different from the control values (Control and Control+NS). 
Hepatosomatic index also increased in TNBS-treated mice when compared to the other 
groups; however these values were not significantly different (Fig. 16). 
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Figure 15. Structural characterization of the NS-protein interaction. A) X-ray diffraction of TNFα+NS, IL-1β+NS, NS, and 
heat-collapsed NS .  XRD results indicate that d-spacing (in brackets [ ]) increases with the presence of TNFα or IL-1β in the 
interlayer of NS.  The absence of a characteristic montmorillonite peak in the heat-collapsed NS sample indicates elimination 
of the internal binding sites.  Transmission electron microscopy results revealed minimal interlayer expansion in the control, 
NS (B).   Evidence of structural exfoliation (expansion of the interlayer) is noted with the presence of TNFα (C) and IL-1β (D).   
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Figure 16. Weight gain and somatic indexes. A) Week-by-week weight change over 4 wks.  Over the course of 4 wks, NS 
treatment resulting in improved weight gain at 2 wks., compared to the TNBS-treated mice (p=0.001). B) Final weight 
according to treatment.  Final weights indicate a significant improvement in weight gain for the NS-treated mice. C) Colonic 
weight to length ratio (mg/cm), a marker of colonic inflammation (p=0.05) The TNBS treatment group had the highest colon 
weight:length ratio, indicating the greatest extent of inflammation  D) Hepatosomatic index ((liver (g)/body weight (g))*100)), 
Hepatosomatic index (HSI) was not significantly different across treatments.   
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Figure 17. Relative expression of serum cytokines. Multiple cytokines were assayed at the end of the study in pooled samples from the 
TNBS and TNBS+NS groups. Analysis was performed in triplicate. Significant decreases in IL-2 (p=0.02), IL-4 (p=0.01), IL-6 (p=0.004), 
and IL-12 (p=0.0007)were noted in the TNBS group compared to the TNBS+NS group. Levels of TNFα, IL-23 and IFNγ decreased in the 
TNBS+NS group compared to the TNBS group, although the effect was not significant.  
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5.3.4 Serum cytokines 
Serum cytokine levels were evaluated upon termination of the study (Fig. 17). 
Compared to the TNBS group, relative expression of IL-2, IL-4, IL-6, and IL-12 was 
significantly decreased in NS+TNBS treated mice compared to the TNBS group. Other 
proinflammatory cytokines including IFNγ, IL-23 and TNFα also decreased with dietary 
inclusion of NS, however, levels were not statistically different than the TNBS group. 
No significant differences in IL-5, IL-10, IL-12, IL-13 and IL-17A levels were detected 
between the TNBS and TNBS+NS group.   
5.3.5 C-reactive Protein Expression  
TNBS-treated mice exhibited increased CRP levels relative to the other treatment 
groups (p=0.0001). Expression of serum CRP revealed that there was no significant 
difference between the Control and Control+NS groups, indicating, the presence of 4% 
NS in the feed alone did not alter the expression of this acute-phase protein (Fig. 18). 
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Figure 18. Expression of C-reactive protein. C-reactive protein (CRP) levels were 
quantified in serum at the end of the study for all four treatment groups. CRP 
significantly increased in the TNBS-treated mice compared to the TNBS+NS group 
(p=0.0001). There were no significant differences between the control and control+NS 
groups.  
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Figure 19. Principal coordinates for Control, TNBS and TNBS+NS. Graphically represented β-diversity for 
Control (red), TNBS (black) and TNBS+NS (blue). Significant clustering differences were observed between 
TNBS and the two other treatment groups, Control and TNBS+NS for unweighted Unifrac distances of 16S 
rRNA genes.   TNBS and TNBS+NS comparison revealed a statistically significant difference (p=0.002) and 
had the greatest correlation (R=0.324).  
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A) B) 
C) 
Figure 20. Alpha diversity analysis of Control, TNBS and TNBS+NS groups. 
Rarefaction curves for 16S ribosomal RNA gene sequences for Control, 
TNBS and TNBS+NS from fecal samples. B) Alpha diversity measured at 
37,000 sequences in Control, TNBS and TNBS+NS treatment groups. The Y 
axis represents the number of observed species, Chao 1 index and Shannon 
index. C) Summary of Alpha diversity data. Number of observed species in 
the TNBS group was significantly lower than in the Control or TNBS+NS 
groups. P=0.03. 
122 
 
5.3.6 16S bacterial rRNA analysis 
There was significant clustering in the TNBS group, when compared to the 
Control and TNBS+NS groups according to the principal coordinates analysis (PCoA) 
for unweighted Unifrac distances (p=0.02, R-statistic=0.1547) (Fig. 19).   
Rarefaction analysis revealed a significant decrease in species richness in the 
TNBS group, compared to the TNBS+NS and Control groups at 37,200 sequences 
(p=0.03) (Fig. 20). The TNBS group exhibited decreased, although not statistically 
significant, Chao 1 index compared to the Control and TNBS+NS groups (p=0.09). The 
Shannon index, which indicates the evenness and abundance of species, did not differ 
significantly between groups, most likely due to the reduction of the number of rare taxa.  
The Weissella genus was significantly more abundant in the TNBS group, 
compared to the other two treatments (Table 17).  None of the other genera varied 
significantly among treatments.  Prevalent bacteria in all three treatment groups included 
Clostridiales, S 24-7, Lachnospiraceae, Oscillospira and Aneroplasm.  
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Table 17. Bacterial taxa    
 
  
Medians % (min-
max%)   
  Control TNBS  TNBS+NS  
Actinobacteria 
0.22 (0.15-
0.31) .22 (0.13-0.32) 
0.18 (0.13-
0.29) 
Corynebacterium 0 (0-0.01) 0.005 (0-0.05) 0 (0-0) 
Arthrobacter 0.01 (0-0.01) 0.005 (0-0.01) 0.01 (0-0.02) 
Bifidobacteriaceae 
0.01 (0.01-
0.02) 0.01 (0.01-0.02) 
0.02 (0.01-
0.02) 
Bifidobacterium  0.005 (0-0.03) 0.01 (0-0.02) 
0.01 (0.01-
0.01) 
Adlercreutzia 
0.095 (0.03-
0.21) 0.095 (0.02-0.16) 
0.05 (0.02-
0.15) 
Collinsella 
0.075 (0.05-
0.11) 0.08 (0.04-0.11) 
0.08 (0.06-
0.12) 
Slackia 0.01(0-0.02) 0.01 (0-0.01) 0.01 (0-0.01) 
Bacteroidetes 
13.55 (3.5-
19.99) 8.47 (5.59-23.74) 
12.68 (3.94-
24.5) 
Bacteroidales 0.01 (0-0.01) 0.01 (0-0.01) 0 (0-0.02) 
Bacteroides 
0.04 (0.02-
0.05) 0.035 (0.02-0.05) 
0.04 (0.03-
0.08) 
Parabacteroides 0.01 (0-0.01) 0 (0-0.01) 0.01 (0-0.01) 
Prevotella 
0.01 (0.01-
0.02) 0.01 (0-0.02) 
0.015 (0.01-
0.02) 
Rikenellaceae 0.005 (0-0.01) 0.01 (0-0.01) 
0.01 (0.01-
0.02) 
S24-7 
13.455 (3.44-
19.91) 8.4 (5.54-23.63) 
12.595 (3.86-
24.33) 
Paraprevotellaceae, 
genus CF231 0.01 (0-0.01) 0.01 (0-0.02) 
0.01 (0.01-
0.02) 
       [Prevotella] 0 (0-0.01) 0.01 (0-0.02) 0.01 (0-0.01) 
Cyanobacteria 0.01 (0-.01) 0 (0-0.01) 0.01 (0-0.01) 
YS2 0.01 (0-0.01) 0 (0-0.01) 0.01 (0-0.01) 
Firmicutes 
80.09 (62.71-
90.48) 
75.32 (55.81-
90.76) 
80.73 (70.56-
92.17) 
Sporosarcina 0 (0-0.01) 0.005 (0-0.01) 0 (0-0.01) 
Staphylococcus 
0.175 (0.03-
0.37) 0.035 (0.01-0.2) 
0.035 (0.01-
0.12) 
 
Gemellales 0.005 (0-0.01) 0 (0-0) 0 (0-0.01) 
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Table 17. Bacterial taxa (continued) 
   
Medians % (min-
max%)   
  Control TNBS  TNBS+NS  
Lactobacillales 0 (0-0.01) 0.01(0-0.03)  0 (0-0.01) 
Enterococcaceae 0 (0-0.01) 0.01 (0-1.43) 0 (0-0.01) 
Enterococcus 0.06 (0.04-0.15) 0.065 (0.05-0.38) 
0.065 (0.03-
0.08) 
Lactobacillus 3.27 (1.69-5) 1.74 (0.76-5.96) 
3.475 (1.53-
7.89) 
Pediococcus 0.01 (0-0.01) 0.01 (0-0.01) 0.01 (0-0.01) 
Leuconostoc 0 (0-0) 0.005 (0-0.05) 0 (0-0) 
Weissella 0 (0-0) 0.15 (0-0.51) 0 (0-0.01) 
Lactococcus 0.01 (0-0.01) 0.01 (0-0.01) 0.01 (0-0.01) 
Streptococcus 0.01 (0.01-0.01) 0.01 (0-0.02) 0.01 (0-0.02) 
Turicibacter 0.04 (0.03-0.05) 0.025 (0.02-0.06) 
0.03 (0.03-
0.04) 
Closridiales 
50.17 (41.37-
64.85) 52.06 (34.3-61.47) 
52.435 (38.94-
62.63) 
Christensenellaceae 0.01 (0-0.04) 0.01 (0-0.05) 
0 (0-0.01) 
 
Clostridiaceae 0.155 (0.11-0.18) 0.135 (0.09-1.18) 
0.125 (0.1-
0.22) 
Clostridium  0.125 (0.09-0.55) 0.18 (0.09-0.75) 
0.14 (0.12-
0.19) 
Dehalobacteri
um 0.11 (0.08-0.12) 0.095 (0.06-0.15) 
0.125 (0.09-
0.23) 
Pseudoramiba
cter_Eubacterium 0 (0-0.01) 0.005 (0-0.01) 0 (0-0.01) 
Lachnospirace
ae 7.255 (5.87-8.01) 5.76 (0.99-12.89) 
7.59 (4.95-
11.12) 
Anaerostipes 0.535 (0.32-1.4) 0.225 (0.03-0.31) 
0.35 (0.03-
0.53) 
Blautia 0.285 (0.2-0.36) 0.215 (0.13-0.3) 
0.325 (0.26-
0.56) 
Coprococcus 1.06 (0.81-1.54) 0.705 (0.26-1.39) 
0.845 (0.43-
1.25) 
Dorea 0.2 (0.12-0.25) 0.185 (0.12-0.97) 
0.25 (0.11-
0.78) 
Epulopiscium 0 (0-0.01) 0.01 (0-0.01) 0 (0-0.01) 
[Ruminococcu
s] 1.44 (0.74-1.61) 1.165 (0.36-3.41) 
1.655 (1.13-
6.05) 
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Table 17. Bacterial taxa (continued) 
   
Medians % (min-
max%)   
  Control TNBS  TNBS+NS  
Peptococcus 
0.02 (0.01-
0.03) 0.02 (0.01-0.03) 
0.035 (0.02-
0.04) 
Peptostreptococc
aceae 
0.06 (0.02-
0.28) 0.06 (0.04-0.07) 0.08 (0.03-0.1) 
Ruminococcaceae 3.91 (2.1-5.11) 3.24 (1.65-6.32) 
4.585 (2.04-
6.84) 
Oscillospira 
5.885 (4.35-
7.76) 4.69 (3.55-7.09) 
5.75 (4.57-
7.24) 
Ruminococcus 
1.565 (0.93-
3.11) 1.9 (1.15-2.44) 
1.45 (1.19-
2.07) 
Veillonellaceae 0.01 (0-0.01) 0.01 (0.01-0.01) 0.01 (0-0.02) 
Phascolarctobacteriu
m 
0.02 (0.01-
0.03) 0.03 (0.01-0.05) 
0.03 (0.01-
0.05) 
[Mogibacteriacea
e] 0.14 (0.1-0.31) 0.175 (0.06-3.62) 
0.115 (0.04-
0.3) 
Erysipelotrichaceae 
0.015 (0.01-
0.04) 0.01 (0-0.53) 
0.01 (0.01-
0.01) 
Allobaculum 0 (0-0.01) 0 (0-0.01) 0.01 (0-0.01) 
Catenibacterium 0.01 (0-0.01) 0.01 (0-0.02) 0.01 (0-0.02) 
Coprobacillus 
0.015 (0.01-
0.05) 0.005 (0-0.28) 0 (0-0.01) 
[Eubacterium]  
0.02 (0.01-
0.03) 0.02 (0.01-0.02) 
0.02 (0.01-
0.03) 
Fusobacteria 0 (0-0.01) 0 (0-0) 0.01 (0-0.01) 
Fusobacterium  0 (0-0.01) 0 (0-0) 0.01 (0-0.01) 
Proteobacteria 
0.07 (0.04-
0.17) 0.11 (0.05-14.36) 
0.06 (0.04-
0.18) 
Desulfovibrionaceae 
0.02 (0.01-
0.03) 0.02 (0.01-0.02) 
0.02 (0.01-
0.03) 
Desulfovibrio 0.01 (0-0.01) 0.01 (0-0.02) 0 (0-0.01) 
Helicobacter 0.005 (0-0.01) 0.005 (0-0.01) 0.01 (0-0.01) 
Enterobacteriace
ae 
0.025 (0.01-
0.06) 0.08 (0-14.1) 
0.02 (0.01-
0.15) 
Spirochaetes 0 (0.0-0.01) 0 (0-0) 0 (0-0.01) 
Treponema 0.005 (0-0.01) 0 (0-0) 0 (0-0.01) 
TM7 0 (0-0.01) 0.01 (0-0.01) 0 (0-0.01) 
F16  0 (0-0.01) 0.005 (0-0.01) 0 (0-0.01) 
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Table 17. Bacterial taxa (continued) 
   
Medians % (min-
max%)   
  Control TNBS  TNBS+NS  
Tenericutes 
8.42 (3.91-
16.97) 7.92 (3.43-23.43) 
6.35 (0.78-
11.58) 
Anaeroplasm 
8.015 (3.46-
16.48) 7.705 (3.37-23) 
6.01 (0.68-
11.37) 
RF39 
0.47 (0.17-
0.85) 0.19 (0.06-0.43) 
0.195 (0.04-
0.64) 
    
 
 
 
5.4 Discussion 
In vitro results (Fig.14 and 15) suggest that TNFα and IL-1β are bound to NS, 
based on the remaining cytokine levels in the supernatants (Fig.14) and change in 
structural morphology of the clay (Fig 15). Figure 15 also implies that these proteins are 
primarily sorbed to the interlayer surface of the clay, indicating that the cytokines are 
attracted to the structural portion of the clay with the greatest negative charge. Multiple 
research groups have characterized interactions between proteins and clay  [382, 387], 
yet none have explored the potential for smectites to sorb proinflammatory cytokines. 
Others have explored the potential for montmorillonites to selectively remove proteins 
from mucosal fluids and these clays have been described to sorb proteins such as 
lysozyme in the blood  [387]. Additionally, similar silicate materials have been saturated 
with a drug in vitro to be used as a therapeutic measure  [388, 389, 390].  Previous 
research indicates that as a silicate structure becomes increasingly saturated with protein, 
that the layered structure becomes separated, or exfoliated  [391].  Similarly, the results 
from this research indicate that the interlayers of NS become “propped open” in the 
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presence of proinflammatory cytokines. The larger the protein and the higher the protein 
concentration, the greater the separation of silicate layers  [392].  Likewise in this study, 
the largest protein, IL-1β (32 kD) created the largest d-spacing within NS, followed by 
TNFα (17.6 kD). Therefore, the size of the protein correlated with the size of the d-
spacing of the NS-protein composite.  
My results from the colitis induction trial provide some evidence for the efficacy 
of NS to alleviate some of the factors associated with GIT inflammation in vivo. It 
should be noted that, similar to other studies, TNBS-treated mice exhibited the largest 
variation in weight. The response to TNBS induction was not uniform throughout the 
mice in each treatment group. Additionally, previous studies have reported an increase in 
colon weight:length ratio as a result of CD and UC induction in mice  [393, 394, 395].  
This study indicates that colon weight:length ratios were significantly different among 
treatments, with TNBS having the lowest colon weight:length ratio. There was a trend 
toward recovery with the addition of NS in the feed in TNBS-induced mice, suggesting 
that NS may have prevented some inflammation and subsequent shortening of the colon 
in the affected areas.  
Crohn’s disease is typically characterized by a Th1/Th17 immune response and is 
associated with upregulation of cytokines such as IL-2, IL-12, IFNγ, TNFα, IL-6 and IL-
1β. Enzyme-linked immunosorbent assay results indicate that NS prevented upregulation 
of inflammatory cytokines associated with TNBS-induced colitis in mice. Furthermore, 
CRP levels, which are often upregulated in CD, were significantly higher in mice treated 
with TNBS, compared to the other groups.  
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Typically, decreased levels of pleiotropic IL-4 in the lamina propria are 
associated with CD. However, we detected higher expression of IL-4 in the TNBS group 
than in the TNBS+NS group. This may be explained by the fact that early CD lesions 
produce higher levels of IL-4 in the early stages of the disease; however, expression of 
this cytokine is reduced as the disease progresses  [396].  Due to the subchronic 
timeframe (4 wk) of the study, the increased expression of IL-4 may indicate that the 
mice were between the early and late stages of CD-like colitis. The presence of NS in the 
feed did not affect the majority of measured anti-inflammatory protein profiles, 
including IL-10 and TGF-β1, suggesting that NS did not inhibit the anti-inflammatory 
response.   
 Numerous studies have focused on the impact of the microbiome in CD. 
Research suggests that an abnormal immune response to the body’s own endogenous 
flora in a genetically susceptible individual can trigger inflammation in the GI 
tract  [397]. Furthermore, dysbiosis has been shown to instigate the initial inflammatory 
response  [165]. There are currently only a few studies that have observed the effects of 
clay supplementation on gastrointestinal microbiota  [149, 398, 399], despite the fact that 
clays have been administered as dietary supplements in both humans and animals for 
many years  [154, 369, 400]. It has been suggested that certain “probiotic” 
microorganisms, such as Lactobacilli, Bifidobacteria and Saccharomyces, are beneficial 
for CD patients  [401, 402, 403]. In this study, levels of Lactobacillus were non-
significantly decreased in the TNBS group (p=0.24), compared to the Control and 
TNBS+NS groups. Bifidobacteria levels, however, remained unchanged in all three 
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treatment groups. Metagenomic analysis has also determined that CD patients have 
reduced intestinal flora diversity compared to healthy controls  [404]. Alterations in the 
gut microbiome in active CD are most likely due to inflammation, resulting in 
permanent alterations in flora, even during remission  [405]. In agreement with these 
findings, I detected a reduction in microbial diversity in the TNBS-treated mice (Fig. 6). 
Importantly, the addition of NS into the feed of TNBS-treated animals resulted in a 
bacterial population that was more closely related to those in the Control group. One 
genus (Weissella) was significantly different in the TNBS group. There were some other 
bacterial genera, such as Blautia sp., that decreased in the TNBS group, although not 
significantly (P=0.09). A decrease in Blautia has been observed in other species with 
IBD-like or other gastrointestinal inflammation  [386, 406]. UniFrac distances, a metric 
of community dissimilarity, are used to measure beta-diversity in the PCoA plots. Our 
results revealed a significant cluster, based on ANOSIM, in the TNBS mice as depicted 
in the PCoA plot. Control and TNBS+NS shared another distinct cluster. Because this is 
the first study to explore the impact of clay supplementation on the colonic microbiome, 
further characterization is needed to fully understand the mechanism by which NS can 
prevent colitis-induced changes in intestinal flora.  
5.5 Conclusions 
Dietary NS inclusion mitigated several TNBS-induced colitis effects, including 
inflammation, colon weight:length ratio, weight loss and microbial profile. One potential 
mechanism for these anti-inflammatory effects is NS-cytokine binding, as described by 
the in vitro capability of NS to bind proinflammatory cytokines.  Another possible 
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mechanism which our data supports is that NS has a protective effect on the 
gastrointestinal microbiome and may promote healthy intestinal flora. Diversity was 
similar for the control and TNBS+NS group, indicating the NS maintains a more diverse 
intestinal microbiome. Due to these findings, I report that NS has potential as an 
alternative or supplemental therapy for CD. Long-term studies are warranted to further 
investigate the effects of NS on GI tract inflammation.   
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6. SUMMARY 
The development of pharmaceutical products are usually targeted for the 
treatment of a specific illness; however many, of these medications are useful in other 
clinical applications.   For example, aluminosilicate clays have been used as “ancient 
medicine” for centuries on all continents to mitigate diarrhea as well as neutralize a 
variety of toxins. One of these aluminosilicate clays (NovaSil, or NS) has been reported 
to prevent mycotoxin-related illness and mortality in animals and exposures from 
aflatoxin-contaminated diets in humans.  The purpose of this research was to explore the 
ability of   NS clay to prevent aflatoxicosis in farm-raised fish and also to further assess 
the anti-inflammatory properties of this clay in vitro and in vivo. Additionally, the 
impact of NS on the gut microbiome was assessed in a TNBS colitis model. More 
importantly, the anti-inflammatory effect of NS may facilitate the treatment of CD or 
other inflammatory disorders of the gastrointestinal tract.  
Aflatoxin exposure is a major public health concern, especially in developing 
countries within the tropical and semitropical regions of the earth, where 4.5 billion 
people and their animals are frequently and highly exposed. The aflatoxins are known to 
cause development of hepatocellular carcinoma and altered immune responses from both 
innate and adaptive systems. Aflatoxins have also been implicated in growth stunting in 
multiple species including fish. The contamination of  susceptible crops causes  major 
economic losses worldwide each year  [407]. Therefore, field-practical and effective pre- 
and postharvest intervention strategies are critically needed and could significantly 
decrease agricultural losses and impact animal and human health. The greatest issue with 
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AFB1 exposure in the aquaculture industry is the lack of documented mycotoxin levels 
in fish feed. Trends to incorporate more plant-based feed ingredients in aquaculture 
feeds have increased the risk for mycotoxin contamination; however, limited information 
is available regarding AFB1 levels in fish feed. Additionally, sensitivity to AFB1 varies 
widely between fish species. For example, rainbow trout and hybrid sturgeon are cited as 
two of the most sensitive species, whereas catfish are known to be more resistant  [21, 
81, 90]. Incorporation of a mycotoxin sorbent into the feed, such as NS clay (or similar 
montmorillonites), could prevent bioavailability and associated toxicity of AFB1 in farm-
raised fish. In addition to rescuing farm-raised fish from toxicity, this clay-based 
intervention strategy may also have an impact on the size and quality of the fillet since 
aflatoxins are known to bioaccumulate in fish tissues  [82]. Regions in Africa, India and 
eastern Asia  utilize fish as a main source of animal-based protein, but are well-known to 
have issues with mycotoxin contamination  [408]. By reducing AFB1 exposure in fish, 
human exposure will also be decreased, especially in geographic regions with frequent 
mycotoxin contamination and high fish consumption.       
Another potential application of NS clay includes treatment of inflammatory 
bowel disorders. As demonstrated in this research, NS has a negatively charged 
interlayer which can sorb positively charged molecules, such as protonated 
proinflammatory cytokines. The NS interlayer was determined to be essential to this 
binding interaction since heat-collapsing the NS clay resulted in very minimal binding to 
the proinflammatory cytokines, TNFα and IL-1β. By sorbing proinflammatory 
cytokines, we suggest that NS might inhibit the “cytokine storm” implicated in CD.  
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This work not only shows that NS may reduce inflammation by binding 
proinflammatory cytokines, but for the first time, it was demonstrated that NS can 
prevent dysbiosis in the gut microbiome. Approximately 1x1014 microbes occupy the 
human gastrointestinal tract, which contains thousands of bacterial phenotypes. The 
entire gut microbiome contains over 100 times as many genes as the human genome.  
Recent scientific evidence has suggested that several ailments, from neurological 
conditions such as ADHD and bipolar disorder to autoimmune disorders such as 
psoriasis, are inherently linked to gastrointestinal flora  [409]. Considering that NS has 
been administered as a feed additive for both humans and animals, further exploration of 
its impact on flora is essential to understanding its mechanism and full health benefits. 
The gut microbiome is now a therapeutic target for treatment of multiple diseases  [410]. 
Antibiotics, probiotics and prebiotics have all been shown to influence the gut 
microbiota, and one course of a commonly prescribed antibiotic  has been shown to 
induce intestinal flora changes for up to 2 years  [411]. Little is known about how other 
medications may influence the gut microbiome, despite the fact that thousands of 
pharmaceuticals are absorbed via the digestive system. It is essential to understand host-
bacterial interactions as a result of therapeutics in order to assess their potentially far-
reaching effects and long-term safety.  
NovaSil has demonstrated safety and efficacy in human clinical intervention 
trials and a variety of animal models designed to prevent AFB1 exposure  [154]. 
Mycotoxin-exposed animals supplemented with NS have shown reduced hepatic lesions, 
improvement in weight gain and growth, and decreased aflatoxin biomarkers of 
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exposure in the urine and blood. Additionally, several studies have tested serum levels of 
vitamins and micronutrients after clay supplementation, and NS does not appear to  
interfere with vitamin and micronutrient utilization  [118].  NovaSil supplementation 
does not affect feed efficiency in farm-raised fish, a finding that coincides with other 
animal and human studies  which  indicate that NS also has acceptable 
palatability  [412].  The therapeutic nature of clays like NS has been known for 
centuries, and understanding their mode of action will lead to improved management for 
a wide range of diseases. Future agricultural and medicinal applications for this 
technology are currently under investigation.  
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